Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
10 "Guideline"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
Article image
Educational exchange in thyroid core needle biopsy diagnosis: enhancing pathological interpretation through guideline integration and peer learning
Agnes Stephanie Harahap, Chan Kwon Jung
J Pathol Transl Med. 2024;58(5):205-213.   Published online July 24, 2024
DOI: https://doi.org/10.4132/jptm.2024.06.24
  • 1,316 View
  • 246 Download
AbstractAbstract PDF
Background
While fine needle aspiration cytology (FNAC) plays an essential role in the screening of thyroid nodules, core needle biopsy (CNB) acts as an alternative method to address FNAC limitations. However, diagnosing thyroid CNB samples can be challenging due to variations in background and levels of experience. Effective training is indispensable to mitigate this challenge. We aim to evaluate the impact of an educational program on improving the accuracy of CNB diagnostics.
Methods
The 2-week observational program included a host mentor pathologist with extensive experience and a visiting pathologist. The CNB classification by The Practice Guidelines Committee of the Korean Thyroid Association was used for the report. Two rounds of reviewing the case were carried out, and the level of agreement between the reviewers was analyzed.
Results
The first-round assessment showed a concordance between two pathologists for 247 thyroid CNB specimens by 84.2%, with a kappa coefficient of 0.74 (indicating substantial agreement). This finding was attributed to the discordance in the use of categories III and V. After peer learning, the two pathologists evaluated 30 new cases, which showed an overall improvement in the level of agreement. The percentage of agreement between pathologists on thyroid CNB diagnosis was 86.7%, as measured by kappa coefficient of 0.80.
Conclusions
This educational program, consisting of guided mentorship and peer learning, can substantially enhance the diagnostic accuracy of thyroid CNB. It is useful in promoting consistent diagnostic standards and contributes to the ongoing development of global pathology practices.
Reviews
Article image
Reevaluating diagnostic categories and associated malignancy risks in thyroid core needle biopsy
Chan Kwon Jung
J Pathol Transl Med. 2023;57(4):208-216.   Published online July 11, 2023
DOI: https://doi.org/10.4132/jptm.2023.06.20
  • 2,050 View
  • 211 Download
  • 5 Web of Science
  • 5 Crossref
AbstractAbstract PDF
As the application of core needle biopsy (CNB) in evaluating thyroid nodules rises in clinical practice, the 2023 Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules have officially recognized its value for the first time. CNB procures tissue samples preserving both histologic structure and cytologic detail, thereby supplying substantial material for an accurate diagnosis and reducing the necessity for repeated biopsies or subsequent surgical interventions. The current review introduces the risk of malignancy within distinct diagnostic categories, emphasizing the implications of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on these malignancy risks. Prior research has indicated diagnostic challenges associated with follicular-patterned lesions, resulting in notable variation within indeterminate diagnostic categories. The utilization of mutation-specific immunostaining in CNB enhances the accuracy of lesion classification. This review underlines the essential role of a multidisciplinary approach in diagnosing follicular-patterned lesions and the potential of mutation-specific immunostaining to strengthen diagnostic consensus and inform patient management decisions.

Citations

Citations to this article as recorded by  
  • Diagnostic implication of thyroid spherules for cytological diagnosis of thyroid nodules
    Heeseung Sohn, Kennichi Kakudo, Chan Kwon Jung
    Cytopathology.2024; 35(3): 383.     CrossRef
  • A Narrative Review of the 2023 Korean Thyroid Association Management Guideline for Patients with Thyroid Nodules
    Eun Kyung Lee, Young Joo Park, Chan Kwon Jung, Dong Gyu Na
    Endocrinology and Metabolism.2024; 39(1): 61.     CrossRef
  • The Diagnostic Role of Repeated Biopsy of Thyroid Nodules with Atypia of Undetermined Significance with Architectural Atypia on Core-Needle Biopsy
    Hye Hyeon Moon, Sae Rom Chung, Young Jun Choi, Tae-Yon Sung, Dong Eun Song, Tae Yong Kim, Jeong Hyun Lee, Jung Hwan Baek
    Endocrinology and Metabolism.2024; 39(2): 300.     CrossRef
  • Core needle biopsy for thyroid nodules assessment-a new horizon?
    David D Dolidze, Serghei Covantsev, Grigorii M Chechenin, Natalia V Pichugina, Anastasia V Bedina, Anna Bumbu
    World Journal of Clinical Oncology.2024; 15(5): 580.     CrossRef
  • Educational exchange in thyroid core needle biopsy diagnosis: enhancing pathological interpretation through guideline integration and peer learning
    Agnes Stephanie Harahap, Chan Kwon Jung
    Journal of Pathology and Translational Medicine.2024; 58(5): 205.     CrossRef
Article image
Recommendations for pathologic practice using digital pathology: consensus report of the Korean Society of Pathologists
Yosep Chong, Dae Cheol Kim, Chan Kwon Jung, Dong-chul Kim, Sang Yong Song, Hee Jae Joo, Sang-Yeop Yi
J Pathol Transl Med. 2020;54(6):437-452.   Published online October 8, 2020
DOI: https://doi.org/10.4132/jptm.2020.08.27
  • 7,378 View
  • 301 Download
  • 17 Web of Science
  • 21 Crossref
AbstractAbstract PDFSupplementary Material
Digital pathology (DP) using whole slide imaging (WSI) is becoming a fundamental issue in pathology with recent advances and the rapid development of associated technologies. However, the available evidence on its diagnostic uses and practical advice for pathologists on implementing DP remains insufficient, particularly in light of the exponential growth of this industry. To inform DP implementation in Korea, we developed relevant and timely recommendations. We first performed a literature review of DP guidelines, recommendations, and position papers from major countries, as well as a review of relevant studies validating WSI. Based on that information, we prepared a draft. After several revisions, we released this draft to the public and the members of the Korean Society of Pathologists through our homepage and held an open forum for interested parties. Through that process, this final manuscript has been prepared. This recommendation contains an overview describing the background, objectives, scope of application, and basic terminology; guidelines and considerations for the hardware and software used in DP systems and the validation required for DP implementation; conclusions; and references and appendices, including literature on DP from major countries and WSI validation studies.

Citations

Citations to this article as recorded by  
  • Performance of externally validated machine learning models based on histopathology images for the diagnosis, classification, prognosis, or treatment outcome prediction in female breast cancer: A systematic review
    Ricardo Gonzalez, Peyman Nejat, Ashirbani Saha, Clinton J.V. Campbell, Andrew P. Norgan, Cynthia Lokker
    Journal of Pathology Informatics.2024; 15: 100348.     CrossRef
  • Swiss digital pathology recommendations: results from a Delphi process conducted by the Swiss Digital Pathology Consortium of the Swiss Society of Pathology
    Andrew Janowczyk, Inti Zlobec, Cedric Walker, Sabina Berezowska, Viola Huschauer, Marianne Tinguely, Joel Kupferschmid, Thomas Mallet, Doron Merkler, Mario Kreutzfeldt, Radivoje Gasic, Tilman T. Rau, Luca Mazzucchelli, Isgard Eyberg, Gieri Cathomas, Kirst
    Virchows Archiv.2024; 485(1): 13.     CrossRef
  • ChatGPT as an aid for pathological diagnosis of cancer
    Shaivy Malik, Sufian Zaheer
    Pathology - Research and Practice.2024; 253: 154989.     CrossRef
  • Possible benefits, challenges, pitfalls, and future perspective of using ChatGPT in pathology
    Durre Aden, Sufian Zaheer, Sabina Khan
    Revista Española de Patología.2024; 57(3): 198.     CrossRef
  • Remote Placental Sign-Out: What Digital Pathology Can Offer for Pediatric Pathologists
    Casey P. Schukow, Jacqueline K. Macknis
    Pediatric and Developmental Pathology.2024; 27(4): 375.     CrossRef
  • Digital Validation in Breast Cancer Needle Biopsies: Comparison of Histological Grade and Biomarker Expression Assessment Using Conventional Light Microscopy, Whole Slide Imaging, and Digital Image Analysis
    Ji Eun Choi, Kyung-Hee Kim, Younju Lee, Dong-Wook Kang
    Journal of Personalized Medicine.2024; 14(3): 312.     CrossRef
  • Pathologists light level preferences using the microscope—study to guide digital pathology display use
    Charlotte Jennings, Darren Treanor, David Brettle
    Journal of Pathology Informatics.2024; 15: 100379.     CrossRef
  • Eye tracking in digital pathology: A comprehensive literature review
    Alana Lopes, Aaron D. Ward, Matthew Cecchini
    Journal of Pathology Informatics.2024; 15: 100383.     CrossRef
  • Diagnostic Assessment of Deep Learning Algorithms for Frozen Tissue Section Analysis in Women with Breast Cancer
    Young-Gon Kim, In Hye Song, Seung Yeon Cho, Sungchul Kim, Milim Kim, Soomin Ahn, Hyunna Lee, Dong Hyun Yang, Namkug Kim, Sungwan Kim, Taewoo Kim, Daeyoung Kim, Jonghyeon Choi, Ki-Sun Lee, Minuk Ma, Minki Jo, So Yeon Park, Gyungyub Gong
    Cancer Research and Treatment.2023; 55(2): 513.     CrossRef
  • Recent application of artificial intelligence on histopathologic image-based prediction of gene mutation in solid cancers
    Mohammad Rizwan Alam, Kyung Jin Seo, Jamshid Abdul-Ghafar, Kwangil Yim, Sung Hak Lee, Hyun-Jong Jang, Chan Kwon Jung, Yosep Chong
    Briefings in Bioinformatics.2023;[Epub]     CrossRef
  • Sustainable development goals applied to digital pathology and artificial intelligence applications in low- to middle-income countries
    Sumi Piya, Jochen K. Lennerz
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Diagnostic proficiency test using digital cytopathology and comparative assessment of whole slide images of cytologic samples for quality assurance program in Korea
    Yosep Chong, Soon Auck Hong, Hoon Kyu Oh, Soo Jin Jung, Bo-Sung Kim, Ji Yun Jeong, Ho-Chang Lee, Gyungyub Gong
    Journal of Pathology and Translational Medicine.2023; 57(5): 251.     CrossRef
  • Real-World Implementation of Digital Pathology: Results From an Intercontinental Survey
    Daniel Gomes Pinto, Andrey Bychkov, Naoko Tsuyama, Junya Fukuoka, Catarina Eloy
    Laboratory Investigation.2023; 103(12): 100261.     CrossRef
  • National digital pathology projects in Switzerland: A 2023 update
    Rainer Grobholz, Andrew Janowczyk, Ana Leni Frei, Mario Kreutzfeldt, Viktor H. Koelzer, Inti Zlobec
    Die Pathologie.2023; 44(S3): 225.     CrossRef
  • Understanding the ethical and legal considerations of Digital Pathology
    Cheryl Coulter, Francis McKay, Nina Hallowell, Lisa Browning, Richard Colling, Philip Macklin, Tom Sorell, Muhammad Aslam, Gareth Bryson, Darren Treanor, Clare Verrill
    The Journal of Pathology: Clinical Research.2022; 8(2): 101.     CrossRef
  • Current Trend of Artificial Intelligence Patents in Digital Pathology: A Systematic Evaluation of the Patent Landscape
    Muhammad Joan Ailia, Nishant Thakur, Jamshid Abdul-Ghafar, Chan Kwon Jung, Kwangil Yim, Yosep Chong
    Cancers.2022; 14(10): 2400.     CrossRef
  • Recent Applications of Artificial Intelligence from Histopathologic Image-Based Prediction of Microsatellite Instability in Solid Cancers: A Systematic Review
    Mohammad Rizwan Alam, Jamshid Abdul-Ghafar, Kwangil Yim, Nishant Thakur, Sung Hak Lee, Hyun-Jong Jang, Chan Kwon Jung, Yosep Chong
    Cancers.2022; 14(11): 2590.     CrossRef
  • Automated Hybrid Model for Detecting Perineural Invasion in the Histology of Colorectal Cancer
    Jiyoon Jung, Eunsu Kim, Hyeseong Lee, Sung Hak Lee, Sangjeong Ahn
    Applied Sciences.2022; 12(18): 9159.     CrossRef
  • Development of quality assurance program for digital pathology by the Korean Society of Pathologists
    Yosep Chong, Jeong Mo Bae, Dong Wook Kang, Gwangil Kim, Hye Seung Han
    Journal of Pathology and Translational Medicine.2022; 56(6): 370.     CrossRef
  • Improving quality control in the routine practice for histopathological interpretation of gastrointestinal endoscopic biopsies using artificial intelligence
    Young Sin Ko, Yoo Mi Choi, Mujin Kim, Youngjin Park, Murtaza Ashraf, Willmer Rafell Quiñones Robles, Min-Ju Kim, Jiwook Jang, Seokju Yun, Yuri Hwang, Hani Jang, Mun Yong Yi, Anwar P.P. Abdul Majeed
    PLOS ONE.2022; 17(12): e0278542.     CrossRef
  • What is Essential is (No More) Invisible to the Eyes: The Introduction of BlocDoc in the Digital Pathology Workflow
    Vincenzo L’Imperio, Fabio Gibilisco, Filippo Fraggetta
    Journal of Pathology Informatics.2021; 12(1): 32.     CrossRef
Article image
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
Soomin Ahn, Ji Won Woo, Kyoungyul Lee, So Yeon Park
J Pathol Transl Med. 2020;54(1):34-44.   Published online November 6, 2019
DOI: https://doi.org/10.4132/jptm.2019.11.03
  • 20,943 View
  • 1,143 Download
  • 137 Web of Science
  • 134 Crossref
AbstractAbstract PDF
Human epidermal growth factor receptor 2 (HER2) protein overexpression and/or HER2 gene amplification is found in about 20% of invasive breast cancers. It is a sole predictive marker for treatment benefits from HER2 targeted therapy and thus, HER2 testing is a routine practice for newly diagnosed breast cancer in pathology. Currently, HER2 immunohistochemistry (IHC) is used for a screening test, and in situ hybridization is used as a confirmation test for HER2 IHC equivocal cases. Since the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines on HER2 testing was first released in 2007, it has been updated to provide clear instructions for HER2 testing and accurate determination of HER2 status in breast cancer. During HER2 interpretation, some pitfalls such as intratumoral HER2 heterogeneity and increase in chromosome enumeration probe 17 signals may lead to inaccurate assessment of HER2 status. Moreover, HER2 status can be altered after neoadjuvant chemotherapy or during metastatic progression, due to biologic or methodologic issues. This review addresses recent updates of ASCO/CAP guidelines and factors complicating in the interpretation of HER2 status in breast cancers.

Citations

Citations to this article as recorded by  
  • Identification of novel chemical scaffolds against kinase domain of cancer causing human epidermal growth factor receptor 2: a systemic chemoinformatic approach
    Faris Alrumaihi
    Journal of Biomolecular Structure and Dynamics.2024; 42(12): 6269.     CrossRef
  • Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer
    Mariia Ivanova, Francesca Maria Porta, Marianna D’Ercole, Carlo Pescia, Elham Sajjadi, Giulia Cursano, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis, Elena Guerini-Rocco, Giuseppe Curigliano, Giuseppe Viale, Nicola Fusco
    Virchows Archiv.2024; 484(1): 3.     CrossRef
  • Analytical Performance Evaluation of a 523-Gene Circulating Tumor DNA Assay for Next-Generation Sequencing–Based Comprehensive Tumor Profiling in Liquid Biopsy Samples
    Johannes Harter, Eleonora Buth, Janina Johaenning, Florian Battke, Maria Kopp, Henning Zelba, Martin Schulze, Jiri Koedding, Saskia Biskup
    The Journal of Molecular Diagnostics.2024; 26(1): 61.     CrossRef
  • Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
    Camille Suydam, Fairouz Chibane, Nicole Brown, Madeleine Schlafly, Alicia H. Arnold, Intisar Ghleilib, Melissa Easley, Joseph White
    Annals of Surgical Oncology.2024; 31(1): 376.     CrossRef
  • HER2 copy number determination in breast cancer using the highly sensitive droplet digital PCR method
    Beate Alinger-Scharinger, Cornelia Kronberger, Georg Hutarew, Wolfgang Hitzl, Roland Reitsamer, Klaassen-Federspiel Frederike, Martina Hager, Thorsten Fischer, Karl Sotlar, Heidi Jaksch-Bogensperger
    Virchows Archiv.2024; 485(1): 53.     CrossRef
  • Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis
    Huiyue Li, Jennifer K. Plichta, Kan Li, Yizi Jin, Samantha M. Thomas, Fei Ma, Li Tang, Qingyi Wei, You-Wen He, Qichen Chen, Yuanyuan Guo, Yueping Liu, Jian Zhang, Sheng Luo
    Breast Cancer Research and Treatment.2024; 204(1): 89.     CrossRef
  • Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer
    Jennifer L. Guerriero, Jia-Ren Lin, Ricardo G. Pastorello, Ziming Du, Yu-An Chen, Madeline G. Townsend, Kenichi Shimada, Melissa E. Hughes, Siyang Ren, Nabihah Tayob, Kelly Zheng, Shaolin Mei, Alyssa Patterson, Krishan L. Taneja, Otto Metzger, Sara M. Tol
    npj Breast Cancer.2024;[Epub]     CrossRef
  • Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer
    Melissa Yuwono Tjota, Jeremy P Segal, Peng Wang
    The Journal of Applied Laboratory Medicine.2024; 9(1): 76.     CrossRef
  • High contrast breast cancer biomarker semi-quantification and immunohistochemistry imaging using upconverting nanoparticles
    Sanathana Konugolu Venkata Sekar, Hui Ma, Katarzyna Komolibus, Gokhan Dumlupinar, Matthias J. Mickert, Krzysztof Krawczyk, Stefan Andersson-Engels
    Biomedical Optics Express.2024; 15(2): 900.     CrossRef
  • HER2-low breast cancer and response to neoadjuvant chemotherapy: a population-based cohort study
    Ximena Baez-Navarro, Mieke R. van Bockstal, Agnes Jager, Carolien H.M. van Deurzen
    Pathology.2024; 56(3): 334.     CrossRef
  • Fast-tracking drug development with biomarkers and companion diagnostics
    Noreen McBrearty, Devika Bahal, Suso Platero
    Journal of Cancer Metastasis and Treatment.2024;[Epub]     CrossRef
  • Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression
    Gary Tozbikian, Savitri Krishnamurthy, Marilyn M. Bui, Michael Feldman, David G. Hicks, Shabnam Jaffer, Thaer Khoury, Shi Wei, Hannah Wen, Paula Pohlmann
    Archives of Pathology & Laboratory Medicine.2024; 148(2): 242.     CrossRef
  • Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer
    Eliya Farah, Chantelle Carbonell, Devon J. Boyne, Darren R. Brenner, Jan-Willem Henning, Daniel Moldaver, Simran Shokar, Winson Y. Cheung
    Cancers.2024; 16(3): 518.     CrossRef
  • Clinical Internal Dosimetry and Biodistribution of 177Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma
    Yoga S. Narwadkar, Rahul V. Parghane, Sudeep Sahu, Sangita Lad, Kamal Deep, Gaurav Wanage, Tejal Suralkar, Sharmila Banerjee, Sudeep Gupta, Sandip Basu, Rajendra A. Badwe
    Clinical Nuclear Medicine.2024; 49(4): e149.     CrossRef
  • Molecular Classifications in Gastric Cancer: A Call for Interdisciplinary Collaboration
    Cristina Díaz del Arco, María Jesús Fernández Aceñero, Luis Ortega Medina
    International Journal of Molecular Sciences.2024; 25(5): 2649.     CrossRef
  • The combined immunohistochemical expression of AMBRA1 and SQSTM1 identifies patients with poorly differentiated cutaneous squamous cell carcinoma at risk of metastasis: A proof of concept study
    Michael H. Alexander, William J. Cousins, Tom Ewen, Andrew P. South, Penny Lovat, Niki Stefanos
    Journal of Cutaneous Pathology.2024; 51(6): 450.     CrossRef
  • Concordance between pathologists and between specimen types in detection of HER2-low breast carcinoma by immunohistochemistry
    Jing Wang, Esther Yoon, Savitri Krishnamurthy
    Annals of Diagnostic Pathology.2024; 70: 152288.     CrossRef
  • Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial
    Lingzhou Zhao, Yan Xing, Changcun Liu, Shaofei Ma, Wenhua Huang, Zhen Cheng, Jinhua Zhao
    Breast Cancer Research.2024;[Epub]     CrossRef
  • Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients
    Yibo Chen, Tianyi Zhang, Rui Zhang, Xuchen Cao
    Cancer Biotherapy and Radiopharmaceuticals.2024; 39(6): 435.     CrossRef
  • Clinicopathological and prognostic significance of VEGF, PDGF-B, and HER2/neu expression in gallbladder cancer
    Pooja Shukla, Kumudesh Mishra, Ratnakar Shukla, Ruchira Vishwakarma, Niraj Kumari, Narendra Krishnani, Anu Behari, Vinay K. Kapoor
    Journal of Cancer Research and Therapeutics.2024; 20(1): 349.     CrossRef
  • Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer
    G. Curigliano, R. Dent, H. Earle, S. Modi, P. Tarantino, G. Viale, S.M. Tolaney
    ESMO Open.2024; 9(4): 102989.     CrossRef
  • Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status
    Sei Na, Milim Kim, Yujun Park, Hyun Jung Kwon, Hee-Chul Shin, Eun-Kyu Kim, Mijung Jang, Sun Mi Kim, So Yeon Park
    Breast Cancer.2024; 31(4): 705.     CrossRef
  • Impact of Neoadjuvant Chemotherapy (NAC) on Biomarker Expression in Breast Cancer
    Suji Lee, Jee Yeon Kim, So Jeong Lee, Chung Su Hwang, Hyun Jung Lee, Kyung Bin Kim, Jung Hee Lee, Dong Hoon Shin, Kyung Un Choi, Chang Hun Lee, Gi Yeong Huh, Ahrong Kim
    Medicina.2024; 60(5): 737.     CrossRef
  • Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future
    Heike Aupperle-Lellbach, Alexandra Kehl, Simone de Brot, Louise van der Weyden
    Veterinary Sciences.2024; 11(5): 199.     CrossRef
  • Clinical Validation of Artificial Intelligence–Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non–Small Cell Lung Cancer
    Hyojin Kim, Seokhwi Kim, Sangjoon Choi, Changhee Park, Seonwook Park, Sergio Pereira, Minuk Ma, Donggeun Yoo, Kyunghyun Paeng, Wonkyung Jung, Sehhoon Park, Chan-Young Ock, Se-Hoon Lee, Yoon-La Choi, Jin-Haeng Chung
    JCO Precision Oncology.2024;[Epub]     CrossRef
  • Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer
    Qiu-Xiao Yu, Ping-Ying Fu, Chi Zhang, Li Li, Wen-Ting Huang
    World Journal of Gastrointestinal Surgery.2024; 16(5): 1395.     CrossRef
  • Lipid nanoparticles-based RNA therapies for breast cancer treatment
    Luigia Serpico, Yuewen Zhu, Renata Faria Maia, Sumedha Sumedha, Mohammad-Ali Shahbazi, Hélder A. Santos
    Drug Delivery and Translational Research.2024; 14(10): 2823.     CrossRef
  • Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges
    Natthawadee Laokulrath, Mihir Gudi, Syed Ahmed Salahuddin, Angela Phek Yoon Chong, Cristine Ding, Jabed Iqbal, Wei Qiang Leow, Benjamin Yongcheng Tan, Gary Tse, Emad Rakha, Puay Hoon Tan
    Histopathology.2024; 85(3): 371.     CrossRef
  • Comprehensive Immunohistochemical Analysis of Epithelial–Mesenchymal Transition Biomarkers in the Invasive Micropapillary Cancer of the Breast
    Ozden Oz, Funda Alkan Tasli, Resmiye Irmak Yuzuguldu, Baha Zengel, Demet Kocatepe Cavdar, Merih Guray Durak, Raika Durusoy, Pranshu Sahgal
    International Journal of Breast Cancer.2024;[Epub]     CrossRef
  • Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies
    Simona Borstnar, Ivana Bozovic-Spasojevic, Ana Cvetanovic, Natalija Dedic Plavetic, Assia Konsoulova, Erika Matos, Lazar Popovic, Savelina Popovska, Snjezana Tomic, Eduard Vrdoljak
    Radiology and Oncology.2024; 58(2): 258.     CrossRef
  • Peer‐to‐peer validation of Ki‐67 scoring in a pathology quality circle as a tool to assess interobserver variability: are we better than we thought?
    Marit Bernhardt, Leonie Weinhold, Christine Sanders, Oliver Hommerding, Jan‐Frederic Lau, Marieta Toma, Verena Tischler, Matthias Schmid, Tomasz Zienkiewicz, Ralf Hildenbrand, Peter Gerlach, Hui Zhou, Martin Braun, Gunnar Müller, Erich Sieber, Christian M
    APMIS.2024; 132(10): 718.     CrossRef
  • Immunohistochemical Expression of Cyclin D1 and p16 in Invasive Breast Carcinoma and Its Association with Clinicopathological Parameters
    Shaivy Malik, Shakthivel V., Sana Ahuja, Charanjeet Ahluwalia
    Indian Journal of Surgical Oncology.2024; 15(4): 864.     CrossRef
  • Novel engineered HER2 specific recombinant protein nanocages for targeted drug delivery
    Javad Kheshti, Mohammad Ahmadyousefi, Meysam Soleimani
    Molecular Biology Reports.2024;[Epub]     CrossRef
  • Circulating C-reactive protein levels as a prognostic biomarker in breast cancer across body mass index groups
    J. B. Holm, E. Baggesen, D. Cronin-Fenton, J. Frystyk, J. M. Bruun, P. Christiansen, S. Borgquist
    Scientific Reports.2024;[Epub]     CrossRef
  • Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer
    Elena Guerini-Rocco, Konstantinos Venetis, Giulia Cursano, Eltjona Mane, Chiara Frascarelli, Francesco Pepe, Mariachiara Negrelli, Edoardo Olmeda, Davide Vacirca, Alberto Ranghiero, Dario Trapani, Carmen Criscitiello, Giuseppe Curigliano, Christian Rolfo,
    Critical Reviews in Oncology/Hematology.2024; 201: 104427.     CrossRef
  • The differences between pure and mixed invasive micropapillary breast cancer: the epithelial–mesenchymal transition molecules and prognosis
    Ozden Oz, Resmiye Irmak Yuzuguldu, Ayse Yazici, Demet Kocatepe Cavdar, Cengiz Yilmaz, Mucteba Ozturk, Hilal Duzel, Duygu Gurel
    Breast Cancer Research and Treatment.2024; 208(1): 41.     CrossRef
  • Best practices for achieving consensus in HER2‐low expression in breast cancer: current perspectives from practising pathologists
    Gary Tozbikian, Marilyn M. Bui, David G Hicks, Shabnam Jaffer, Thaer Khoury, Hannah Y Wen, Savitri Krishnamurthy, Shi Wei
    Histopathology.2024; 85(3): 489.     CrossRef
  • Consensus Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2)-Low Testing in Breast Cancer in Malaysia
    Pathmanathan Rajadurai, Sarala Ravindran, Bang Rom Lee, Suria Hayati Md Pauzi, Seow Fan Chiew, Kean Hooi Teoh, Navarasi S. Raja Gopal, Mastura Md Yusof, Cheng Har Yip
    Cancers.2024; 16(13): 2325.     CrossRef
  • Revolutionizing Pathology with Artificial Intelligence: Innovations in Immunohistochemistry
    Diana Gina Poalelungi, Anca Iulia Neagu, Ana Fulga, Marius Neagu, Dana Tutunaru, Aurel Nechita, Iuliu Fulga
    Journal of Personalized Medicine.2024; 14(7): 693.     CrossRef
  • A Comprehensive Model Outperformed the Single Radiomics Model in Noninvasively Predicting the HER2 Status in Patients with Breast Cancer
    Weimin Liu, Yiqing Yang, Xiaohong Wang, Chao Li, Chen Liu, Xiaolei Li, Junzhe Wen, Xue Lin, Jie Qin
    Academic Radiology.2024;[Epub]     CrossRef
  • Interobserver Variability in HER‐2 Immunostaining Interpretation of Metastatic HER2 Low Breast Cancers in Cytology Specimens
    Niyati Desai, Courtney F. Connelly, Simon Sung, Adela Cimic, Swikrity U. Baskota
    Diagnostic Cytopathology.2024; 52(12): 722.     CrossRef
  • Weakly-supervised deep learning models enable HER2-low prediction from H &E stained slides
    Renan Valieris, Luan Martins, Alexandre Defelicibus, Adriana Passos Bueno, Cynthia Aparecida Bueno de Toledo Osorio, Dirce Carraro, Emmanuel Dias-Neto, Rafael A. Rosales, Jose Marcio Barros de Figueiredo, Israel Tojal da Silva
    Breast Cancer Research.2024;[Epub]     CrossRef
  • Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2
    Sana Ahuja, Adil Aziz Khan, Sufian Zaheer
    Pathology - Research and Practice.2024; 262: 155550.     CrossRef
  • Systematic review of added immunotherapy in traditional treatment for HER2 positive breast cancer patients
    Rohan Choudhari
    Innovative Practice in Breast Health.2024; 3-4: 100013.     CrossRef
  • Detecting early-stage breast cancer with GATA3-positive circulating tumor cells
    Chun-Hsin Hsieh, Ya-Herng Chang, Pei-Ying Ling, Ying-Tai Jin, Pei-Hsuan Lo, Hei-Jen Jou
    Taiwanese Journal of Obstetrics and Gynecology.2024; 63(5): 745.     CrossRef
  • First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors
    Jian Zhang, Yiqun Du, Yanchun Meng, Xiaojun Liu, Yuxin Mu, Yunpeng Liu, Yehui Shi, Jufeng Wang, Aimin Zang, Shanzhi Gu, Tianshu Liu, Huan Zhou, Hongqian Guo, Silong Xiang, Xialu Zhang, Suqiong Wu, Huanhuan Qi, Mengke Li, Xichun Hu
    npj Precision Oncology.2024;[Epub]     CrossRef
  • Targeting CD276 for T cell-based immunotherapy of breast cancer
    Ilona Hagelstein, Laura Wessling, Alexander Rochwarger, Latifa Zekri, Boris Klimovich, Christian M. Tegeler, Gundram Jung, Christian M. Schürch, Helmut R. Salih, Martina S. Lutz
    Journal of Translational Medicine.2024;[Epub]     CrossRef
  • Correlation of Androgen Receptor Expression With Ki67 Proliferative Index and Other Clinicopathological Characteristics in Invasive Mammary Carcinomas
    D Keerthana Devi, V Pavithra, Leena D Joseph, Chithra Bhanu Challa
    Cureus.2024;[Epub]     CrossRef
  • CD81-guided heterologous EVs present heterogeneous interactions with breast cancer cells
    Elena Gurrieri, Giulia Carradori, Michela Roccuzzo, Michael Pancher, Daniele Peroni, Romina Belli, Caterina Trevisan, Michela Notarangelo, Wen-Qiu Huang, Agata S. A. Carreira, Alessandro Quattrone, Guido Jenster, Timo L. M. Ten Hagen, Vito Giuseppe D’Agos
    Journal of Biomedical Science.2024;[Epub]     CrossRef
  • Multiparametric MRI Radiomics With Machine Learning for Differentiating HER2-Zero, -Low, and -Positive Breast Cancer: Model Development, Testing, and Interpretability Analysis
    Yongxin Chen, Siyi Chen, Wenjie Tang, Qingcong Konge, Zhidan Zhong, Xiaomeng Yu, Yi Sui, Wenke Hu, Xinqing Jiang, Yuan Guo
    American Journal of Roentgenology.2024;[Epub]     CrossRef
  • Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer
    Anna Pous, Adrià Bernat-Peguera, Assumpció López-Paradís, Beatriz Cirauqui, Vanesa Quiroga, Iris Teruel, Eudald Felip, Angelica Ferrando-Díez, Milana Bergamino, Laia Boronat, Margarita Romeo, Gemma Soler, Christian Mariño, Paula Rodríguez-Martínez, Laura
    Therapeutic Advances in Medical Oncology.2024;[Epub]     CrossRef
  • Liquid biopsy-based technologies: a promising tool for biomarker identification in her2-low breast cancer patients for improved therapeutic outcomes
    Aldo D’Alessandro, Anca Florentina Deaconu, Sandro Mandolesi, Federico Pio Fabrizio, Massimo Lombardi, Giovanna Liguori, Giovanni Pepe, Nicola Marino, Aureliano Stingi, Alessandro D’Alessandro, Antonio Giordano
    Journal of Cancer Metastasis and Treatment.2024;[Epub]     CrossRef
  • Surgical Management of the Axilla in HR+/HER2– Breast Cancer in the Z1071 Era: A Propensity Score-Matched Analysis of the National Cancer Database
    Vayda R. Barker, Samer A. Naffouje, Melissa A. Mallory, Susan A. Hoover, Christine Laronga
    Annals of Surgical Oncology.2023; 30(13): 8371.     CrossRef
  • Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer
    Yuan Guo, Xiaotong Xie, Wenjie Tang, Siyi Chen, Mingyu Wang, Yaheng Fan, Chuxuan Lin, Wenke Hu, Jing Yang, Jialin Xiang, Kuiming Jiang, Xinhua Wei, Bingsheng Huang, Xinqing Jiang
    European Radiology.2023; 34(2): 899.     CrossRef
  • Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
    Lan Deng, Le Zhao, Lifen Liu, Haomin Huang
    Open Life Sciences.2023;[Epub]     CrossRef
  • HER2-low expression in patients with advanced or metastatic solid tumors
    B. Uzunparmak, C. Haymaker, G. Raso, S. Masciari, L. Wang, H. Lin, A. Gorur, B. Kirby, A.-M. Cimo, A. Kennon, Q. Ding, G. Urschel, Y. Yuan, G. Feng, Y. Rizvi, A. Hussain, C. Zhu, P. Kim, G. Abbadessa, V. Subbiah, T.A. Yap, J. Rodon, S.A. Piha-Paul, F. Mer
    Annals of Oncology.2023; 34(11): 1035.     CrossRef
  • Data on 2D culture characterisation of potential markers in human HER2-positive breast cancer cell lines
    Son H. Pham, Lyn R. Griffiths, Rachel K. Okolicsanyi, Larisa M. Haupt
    Data in Brief.2023; 46: 108880.     CrossRef
  • Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors
    Christiane Palm, Catherine E. Connolly, Regina Masser, Barbara Padberg Sgier, Eva Karamitopoulou, Quentin Simon, Beata Bode, Marianne Tinguely
    Diagnostics.2023; 13(1): 168.     CrossRef
  • Gene amplification mutations originate prior to selective stress inAcinetobacter baylyi
    Jennifer A Herrmann, Agata Koprowska, Tesa J Winters, Nancy Villanueva, Victoria D Nikityuk, Feini Pek, Elizabeth M Reis, Constancia Z Dominguez, Daniel Davis, Eric McPherson, Staci R Rocco, Cynthia Recendez, Shyla M Difuntorum, Kelly Faeth, Mario D Lopez
    G3 Genes|Genomes|Genetics.2023;[Epub]     CrossRef
  • Flow Rate-Independent Multiscale Liquid Biopsy for Precision Oncology
    Jie Wang, Robert Dallmann, Renquan Lu, Jing Yan, Jérôme Charmet
    ACS Sensors.2023; 8(3): 1200.     CrossRef
  • Single-cell HER2 quantification via instant signal amplification in microdroplets
    Xiaoxian Liu, Yifan Zhu, Caoxin Li, Yanyun Fang, Jinna Chen, Fei Xu, Yanqing Lu, Perry Ping Shum, Ying Liu, Guanghui Wang
    Analytica Chimica Acta.2023; 1251: 340976.     CrossRef
  • Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine
    Daniela Miladinova
    Frontiers in Molecular Biosciences.2023;[Epub]     CrossRef
  • CORRELATION BETWEEN DIFFERENT CLINICOPATHOLOGICAL PARAMETERS AND MOLECULAR SUBTYPES OF FEMALE BREAST CARCINOMA IN SOUTH REGION OF IRAQ
    Yassir Alaa Muhammed Hassan Shubbar
    Wiadomości Lekarskie.2023; 76(1): 97.     CrossRef
  • Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test
    Elham Sajjadi, Elena Guerini-Rocco, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis, Mariia Ivanova, Nicola Fusco
    Frontiers in Molecular Biosciences.2023;[Epub]     CrossRef
  • Protective Effect of HER2 Gene Polymorphism rs24537331 in the Outcome of Canine Mammary Tumors
    Ana Canadas-Sousa, Marta Santos, Patrícia Dias-Pereira
    Animals.2023; 13(8): 1384.     CrossRef
  • Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review
    Jin Wang, Dongying Liao, Xuemin Zhang, Changhong Miao, Kuang Chen
    Breast Cancer: Targets and Therapy.2023; Volume 15: 281.     CrossRef
  • HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
    Marina Popović, Tajana Silovski, Marija Križić, Natalija Dedić Plavetić
    International Journal of Molecular Sciences.2023; 24(9): 8206.     CrossRef
  • HER2-Low Breast Cancer—Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast
    Aditya Bardia, Giuseppe Viale
    Targeted Oncology.2023; 18(3): 313.     CrossRef
  • Histopathological and immunohistochemical analysis of predictive and prognostic markers in spontaneous canine mammary cancer
    Vladimír Tancoš, Marcel Kovalik, Martin Levkut, Martina Bobrovská, Petra Kolenčíková, Ľubomír Straka, Zuzana Ševčíková, Ondřej Škor, Martina Antošová, Lukáš Plank, Keith L. Thoday
    Acta Veterinaria Brno.2023; 92(2): 143.     CrossRef
  • Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study
    Timothy Qi, Yanguang Cao
    European Journal of Pharmaceutical Sciences.2023; 186: 106467.     CrossRef
  • The Effect of HER2-Low Status on Pathological Complete Response and Survival in Triple-Negative Breast Cancer: A Systemic Review and Meta-Analysis
    Yakup Ergun, Baran Akagunduz, Cengiz Karacin, Sema Turker, Gokhan Ucar
    Clinical Breast Cancer.2023; 23(6): 567.     CrossRef
  • Efficacy, toxicity and prognostic factors of pyrotinib‑involved neoadjuvant therapy in HER2‑positive breast cancer: A retrospective study
    Hao Wang, Hailing Cao, Zhiyun Guo
    Oncology Letters.2023;[Epub]     CrossRef
  • Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
    Feng Ye, Saikat Dewanjee, Yuehua Li, Niraj Kumar Jha, Zhe-Sheng Chen, Ankush Kumar, Vishakha, Tapan Behl, Saurabh Kumar Jha, Hailin Tang
    Molecular Cancer.2023;[Epub]     CrossRef
  • Weakly supervised bilayer convolutional network in segmentation of HER2 related cells to guide HER2 targeted therapies
    Ching-Wei Wang, Kun-Lin Lin, Hikam Muzakky, Yi-Jia Lin, Tai-Kuang Chao
    Computerized Medical Imaging and Graphics.2023; 108: 102270.     CrossRef
  • Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods
    Francesca Maria Porta, Elham Sajjadi, Konstantinos Venetis, Chiara Frascarelli, Giulia Cursano, Elena Guerini-Rocco, Nicola Fusco, Mariia Ivanova
    Journal of Personalized Medicine.2023; 13(7): 1176.     CrossRef
  • HER2 Equivocal (Score = 2+) Breast Carcinoma Cases Identified by Immunohistochemistry at a South African Hospital. What is the Impact of Fluorescent In Situ Hybridization Testing?
    Reena Dhansukh Mohanlal, Nikki Bouwer, Pascale Willem
    Applied Immunohistochemistry & Molecular Morphology.2023; 31(8): 555.     CrossRef
  • Discordance of HER2 Expression and/or Amplification on Repeat Testing
    Timothy P. DiPeri, Kathleen Kong, Kaushik Varadarajan, Daniel D. Karp, Jaffer A. Ajani, Shubham Pant, Michael F. Press, Sarina A. Piha-Paul, Ecaterina E. Dumbrava, Funda Meric-Bernstam
    Molecular Cancer Therapeutics.2023; 22(8): 976.     CrossRef
  • Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes
    Mariausilia Franchina, Cristina Pizzimenti, Vincenzo Fiorentino, Maurizio Martini, Giuseppina Rosaria Rita Ricciardi, Nicola Silvestris, Antonio Ieni, Giovanni Tuccari
    International Journal of Molecular Sciences.2023; 24(16): 12795.     CrossRef
  • Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes
    Kuikui Jiang, Danyang Zhou, Fei Xu, Wen Xia, Qiufan Zheng, Qianyi Lu, Rongzhen Luo, Ruoxi Hong, Shusen Wang
    BMC Cancer.2023;[Epub]     CrossRef
  • Single domain antibodies specific for HER2 dimerization domain effectively disrupts HER2 dimerization
    Ahmad Najafi, Reza Valadan, Hossein Asgarian-Omran, Alireza Rafiei, Mohsen Tehrani
    International Immunopharmacology.2023; 124: 110999.     CrossRef
  • Récepteur du facteur de croissance épidermique HER2, tests utilisés pour rechercher son amplification dans le cancer du sein : principes et limites
    Imane Eliahiai, Mohammed Eljiar, Sanae Chaib, Jinane KHarmoum, Mariame Chraïbi
    Bulletin du Cancer.2023; 110(12): 1301.     CrossRef
  • Integrated Molecular Characterization of HER2-Low Breast Cancer Using Next Generation Sequencing (NGS)
    Jean-Louis Merlin, Marie Husson, Nassim Sahki, Pauline Gilson, Vincent Massard, Alexandre Harlé, Agnès Leroux
    Biomedicines.2023; 11(12): 3164.     CrossRef
  • GLUCOSE LEVELS OF PLEURAL EFFUSION FLUID AND HER2 STATUS IN PLEURAL-METASTATIC BREAST CANCER
    Muhammad Dhanny Irawan, Desak Gede Agung Suprabawati, Heru Purwanto
    Majalah Biomorfologi.2023; 33(2): 75.     CrossRef
  • Design of a Ratiometric Plasmonic Biosensor for Herceptin Detection in HER2-Positive Breast Cancer
    Neda Shahbazi, Rouholah Zare-Dorabei, Seyed Morteza Naghib
    ACS Biomaterials Science & Engineering.2022; 8(2): 871.     CrossRef
  • A highly sensitive nanobiosensor based on aptamer-conjugated graphene-decorated rhodium nanoparticles for detection of HER2-positive circulating tumor cells
    Mahdi Sadeghi, Soheila Kashanian, Seyed Morteza Naghib, Esfandyar Askari, Fateme Haghiralsadat, Davood Tofighi
    Nanotechnology Reviews.2022; 11(1): 793.     CrossRef
  • Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
    Carrie S. Wynn, Shou-Ching Tang
    Cancer and Metastasis Reviews.2022; 41(1): 193.     CrossRef
  • Electroanalytical overview: screen-printed electrochemical sensing platforms for the detection of vital cardiac, cancer and inflammatory biomarkers
    Robert D. Crapnell, Alejandro Garcia-Miranda Ferrari, Nina C. Dempsey, Craig E. Banks
    Sensors & Diagnostics.2022; 1(3): 405.     CrossRef
  • FTO genotype was associated with breast cancer in HER2 negative patients
    Fateme Montazeri, Hossein Hatami, Soroor Fathi, Naeemeh Hasanpour Ardekanizadeh, Fatemeh Bourbour, Samira Rastgoo, Fatemeh Shafiee, Mohammad Esmail Akbari, Maryam Gholamalizadeh, Seyed Alireza Mosavi Jarrahi, Saeid Doaei
    Clinical Nutrition ESPEN.2022; 49: 495.     CrossRef
  • Breast Cancer Human Epidermal Growth Factor Receptor 2 mRNA Molecular Testing Compared to Immunohistochemistry with Correlation to Neoadjuvant Therapy Response
    Mahmoud Behairy, Samia Mohamed Gabal, Mohamed Sherif Negm
    Open Access Macedonian Journal of Medical Sciences.2022; 10(A): 352.     CrossRef
  • Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review
    Noortje Verschoor, Teoman Deger, Agnes Jager, Stefan Sleijfer, Saskia M. Wilting, John W.M. Martens
    Cancer Treatment Reviews.2022; 106: 102384.     CrossRef
  • RETRACTED: Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer Patients
    Hui Liu, Xiaoyan Hu, Lingyun Wang, Tao Du, Jing Feng, Ming Li, Lei Liu, Xiaofang Liu
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • Use of Radionuclide-Based Imaging Methods in Breast Cancer
    Betül Altunay, Agnieszka Morgenroth, Felix M. Mottaghy
    Seminars in Nuclear Medicine.2022; 52(5): 561.     CrossRef
  • Functional regulations between genetic alteration-driven genes and drug target genes acting as prognostic biomarkers in breast cancer
    Li Wang, Lei Yu, Jian Shi, Feng Li, Caiyu Zhang, Haotian Xu, Xiangzhe Yin, Lixia Wang, Shihua Lin, Anastasiia Litvinova, Yanyan Ping, Shangwei Ning, Hongying Zhao
    Scientific Reports.2022;[Epub]     CrossRef
  • Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
    Anastasia Alataki, Mitch Dowsett
    Endocrine-Related Cancer.2022; 29(8): R105.     CrossRef
  • The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
    Olga D. Bragina, Sergei M. Deyev, Vladimir I. Chernov, Vladimir M. Tolmachev
    Acta Naturae.2022; 14(2): 4.     CrossRef
  • Deriving tumor purity from cancer next generation sequencing data: applications for quantitative ERBB2 (HER2) copy number analysis and germline inference of BRCA1 and BRCA2 mutations
    Stephanie E. Siegmund, Danielle K. Manning, Phani K. Davineni, Fei Dong
    Modern Pathology.2022; 35(10): 1458.     CrossRef
  • Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer
    Matti Aapro, Fatima Cardoso, Giuseppe Curigliano, Alexandru Eniu, Joseph Gligorov, Nadia Harbeck, Andreas Mueller, Olivia Pagani, Shani Paluch-Shimon, Elzbieta Senkus, Beat Thürlimann, Khalil Zaman
    The Breast.2022; 66: 145.     CrossRef
  • [Retracted] Application of Fluorescence In Situ Hybridization Assisted by Fluorescence Microscope in Detection of Her2 Gene in Breast Cancer Patients
    Fang Lu, Tingting Zhou, Yan Liu, Liying Song, Bin Zhang, Yuyan Li, Sorayouth Chumnanvej
    Contrast Media & Molecular Imaging.2022;[Epub]     CrossRef
  • High sensitivity label-free detection of HER2 using an Al–GaN/GaN high electron mobility transistor-based biosensor
    Shivanshu Mishra, Pharyanshu Kachhawa, Amber Kumar Jain, Rajiv Ranjan Thakur, Nidhi Chaturvedi
    Lab on a Chip.2022; 22(21): 4129.     CrossRef
  • Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP Guidelines
    B. R. Nagarjun, Biren Parikh, Manaswi Nareshkumar Patel, Pina J. Trivedi, Dharmesh M. Patel
    South Asian Journal of Cancer.2022; 11(04): 281.     CrossRef
  • S‑phase fraction, lymph node status and disease staging as the main prognostic factors to differentiate between young and older patients with invasive breast carcinoma
    António Pinto, João Matos, Teresa Pereira, Giovani Silva, Saudade André
    Oncology Letters.2022;[Epub]     CrossRef
  • Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling
    Alina Batzilla, Junyan Lu, Jarno Kivioja, Kerstin Putzker, Joe Lewis, Thorsten Zenz, Wolfgang Huber, James Gallo
    PLOS Computational Biology.2022; 18(8): e1010438.     CrossRef
  • Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins
    O. D. Bragina, V. I. Chernov, S. M. Deyev, V. M. Tolmachev
    Bulletin of Siberian Medicine.2022; 21(3): 132.     CrossRef
  • Molecular Pathology of Gastric Cancer
    Moonsik Kim, An Na Seo
    Journal of Gastric Cancer.2022; 22(4): 264.     CrossRef
  • Loss of NECTIN1 triggers melanoma dissemination upon local IGF1 depletion
    Julien Ablain, Amira Al Mahi, Harriet Rothschild, Meera Prasad, Sophie Aires, Song Yang, Maxim E. Dokukin, Shuyun Xu, Michelle Dang, Igor Sokolov, Christine G. Lian, Leonard I. Zon
    Nature Genetics.2022; 54(12): 1839.     CrossRef
  • Advanced diagnosis technologies for HER2 breast cancer markers
    Mengxue Zhang
    Highlights in Science, Engineering and Technology.2022; 14: 44.     CrossRef
  • An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)
    Aleix Prat, Aditya Bardia, Giuseppe Curigliano, M. Elizabeth H. Hammond, Sibylle Loibl, Sara M. Tolaney, Giuseppe Viale
    JAMA Oncology.2022; 8(11): 1676.     CrossRef
  • Development of T-cell engagers selective for cells co-expressing two antigens
    Danielle M. Dicara, Sunil Bhakta, Mary Ann Go, James Ziai, Ron Firestein, Bill Forrest, Chen Gu, Steven R. Leong, Genee Lee, Shang-Fan Yu, Andrew G. Polson, Nicholas J. Agard
    mAbs.2022;[Epub]     CrossRef
  • The clinical significance of HER2 expression in DCIS
    Ioanna Akrida, Francesk Mulita
    Medical Oncology.2022;[Epub]     CrossRef
  • Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2
    Rachel Occhiogrosso Abelman, Arielle Medford, Laura Spring, Aditya Bardia
    The Cancer Journal.2022; 28(6): 423.     CrossRef
  • The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients
    Ugur Gezer, Abel J. Bronkhorst, Stefan Holdenrieder
    Diagnostics.2022; 12(12): 3042.     CrossRef
  • Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
    Ye Yuan, Xumei Liu, Yi Cai, Wenyuan Li
    Systematic Reviews.2022;[Epub]     CrossRef
  • Interactions dietary components with expression level of breast cancer-related genes
    Fatemeh Bourbour, Azam Pourtaheri, Khadijeh Abbasi, Naeemeh Hasanpour Ardekanizadeh, Maryam Gholamalizadeh, Azadeh Hajipour, Sepideh Abdollahi, Seyedeh Elaheh Bagheri, Mina Ahmadzadeh, Saeid Doaei, Arezoo Haghighian
    Egyptian Journal of Medical Human Genetics.2022;[Epub]     CrossRef
  • HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging
    Betül Altunay, Agnieszka Morgenroth, Mohsen Beheshti, Andreas Vogg, Nicholas C. L. Wong, Hong Hoi Ting, Hans-Jürgen Biersack, Elmar Stickeler, Felix M. Mottaghy
    European Journal of Nuclear Medicine and Molecular Imaging.2021; 48(5): 1371.     CrossRef
  • Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge
    Christian Jackisch, Patricia Cortazar, Charles E. Geyer, Luca Gianni, Joseph Gligorov, Zuzana Machackova, Edith A. Perez, Andreas Schneeweiss, Sara M. Tolaney, Michael Untch, Andrew Wardley, Martine Piccart
    Cancer Treatment Reviews.2021; 99: 102229.     CrossRef
  • Histologic Patterns of Cutaneous Metastases of Breast Carcinoma: A Clinicopathologic Study of 232 Cases
    Shira Ronen, David Suster, Wei-Shen Chen, Natali Ronen, Sri Krishna C. Arudra, Celestine Trinidad, Doina Ivan, Victor G. Prieto, Saul Suster
    The American Journal of Dermatopathology.2021; 43(6): 401.     CrossRef
  • Standardized pathology report for breast cancer
    Soo Youn Cho, So Yeon Park, Young Kyung Bae, Jee Yeon Kim, Eun Kyung Kim, Woo Gyeong Kim, Youngmee Kwon, Ahwon Lee, Hee Jin Lee, Ji Shin Lee, Jee Young Park, Gyungyub Gong, Hye Kyoung Yoon
    Journal of Pathology and Translational Medicine.2021; 55(1): 1.     CrossRef
  • The impact of oral contraceptive use on breast cancer risk: State of the art and future perspectives in the era of 4P medicine
    R. Bonfiglio, M.L. Di Pietro
    Seminars in Cancer Biology.2021; 72: 11.     CrossRef
  • The Co-Expression of Melanoma-Antigen Family a Proteins and New York Esophageal Squamous Cell Carcinoma-1 in Breast Cancer: A Pilot Study
    Yu-Xin Wang, Feng-Lian Li, Li-Xin Du, Jun-Fang Liu, Li-Gang Huo, Shu-Qing Li, Bin Tian
    Cancer Management and Research.2021; Volume 13: 6123.     CrossRef
  • Targeting HER2 protein in individual cells using ICP-MS detection and its potential as prognostic and predictive breast cancer biomarker
    A. Fernández Asensio, M. Corte-Rodríguez, J. Bettmer, L.M. Sierra, M. Montes-Bayón, E. Blanco- González
    Talanta.2021; 235: 122773.     CrossRef
  • Development of a 99mTc-Labeled Single-Domain Antibody for SPECT/CT Assessment of HER2 Expression in Breast Cancer
    Lingzhou Zhao, Changcun Liu, Yan Xing, Jin He, Jim O’Doherty, Wenhua Huang, Jinhua Zhao
    Molecular Pharmaceutics.2021; 18(9): 3616.     CrossRef
  • WITHDRAWN: Nouvelles stratégies thérapeutiques dans les cancers du sein HER2-surexprimé
    Benoîte Mery, Philippe Toussaint, Pierre-Etienne Heudel, Armelle Dufresne, Mélodie Carbonnaux, Hélène Vanacker, Thomas Bachelot, Olivier Trédan
    Bulletin du Cancer.2021;[Epub]     CrossRef
  • Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases
    Emad A. Rakha, Islam M. Miligy, Cecily M. Quinn, Elena Provenzano, Abeer M. Shaaban, Caterina Marchiò, Michael S. Toss, Grace Gallagy, Ciara Murray, Janice Walshe, Ayaka Katayama, Karim Eldib, Nahla Badr, Bruce Tanchel, Rebecca Millican-Slater, Colin Purd
    British Journal of Cancer.2021; 124(11): 1836.     CrossRef
  • Loss of HER2‐positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes
    Catherine L. Wetzel, Thomas L. Sutton, Stuart Gardiner, Maryam Farinola, Nathalie Johnson, Jennifer R. Garreau
    Journal of Surgical Oncology.2021; 124(8): 1224.     CrossRef
  • Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy
    Lun Li, Min Chen, Shuyue Zheng, Hanlu Li, Weiru Chi, Bingqiu Xiu, Qi Zhang, Jianjing Hou, Jia Wang, Jiong Wu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • tRNA‐derived fragments: tRF‐Gly‐CCC‐046, tRF‐Tyr‐GTA‐010 and tRF‐Pro‐TGG‐001 as novel diagnostic biomarkers for breast cancer
    Yue Zhang, Zhao Bi, Xiaohan Dong, Miao Yu, Kangyu Wang, Xingguo Song, Li Xie, Xianrang Song
    Thoracic Cancer.2021; 12(17): 2314.     CrossRef
  • Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3
    L. De Cock, J. Heylen, A. Wildiers, K. Punie, A. Smeets, C. Weltens, P. Neven, J. Billen, A. Laenen, H. Wildiers
    ESMO Open.2021; 6(4): 100203.     CrossRef
  • Standardized Pathology Report for Breast Cancer
    Soo Youn Cho, So Yeon Park, Young Kyung Bae, Jee Yeon Kim, Eun Kyung Kim, Woo Gyeong Kim, Youngmee Kwon, Ahwon Lee, Hee Jin Lee, Ji Shin Lee, Jee Young Park, Gyungyub Gong, Hye Kyoung Yoon
    Journal of Breast Cancer.2021; 24(1): 1.     CrossRef
  • Circular RNA circ-ERBB2 promotes HER2-positive breast cancer progression and metastasis via sponging miR-136-5p and miR-198
    Jin-xiu Zhong, Yun-yuan Kong, Rong-guang Luo, Guo-jin Xia, Wen-xing He, Xue-zhong Chen, Wei-wei Tan, Qing-jie Chen, Yu-yin Huang, Yan-xing Guan
    Journal of Translational Medicine.2021;[Epub]     CrossRef
  • Nouvelles stratégies thérapeutiques dans les cancers du sein HER2-surexprimé
    Benoîte Mery, Philippe Toussaint, Pierre-Etienne Heudel, Armelle Dufresne, Mélodie Carbonnaux, Hélène Vanacker, Thomas Bachelot, Olivier Trédan
    Bulletin du Cancer.2021; 108(11): 11S8.     CrossRef
  • Association of Estrogen and Progesterone Receptors with Clinicopathological Prognostic Factors in Breast Cancer
    Ali Abdul Hadi Abdul-Kareem, Qahtan A. Mahdi
    Medical Journal of Babylon.2021; 18(2): 111.     CrossRef
  • HER2 alterations in non-small-cell lung cancer – Druggable or undruggable?
    Suresh Kumar Bondili, Ravindra Nandhana, Vanita Noronha, Swayamprabha Pawar, Nandini Menon, Omshree Shetty, Anuradha Chougule, Abhishek Mahajan, Rajiv Kumar, Vijay M. Patil, Amit Joshi, Kumar Prabhash
    Cancer Research, Statistics, and Treatment.2021; 4(2): 374.     CrossRef
  • UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer
    Evgenii L. Guryev, Anita S. Smyshlyaeva, Natalia Y. Shilyagina, Evgeniya A. Sokolova, Samah Shanwar, Alexey B. Kostyuk, Alexander V. Lyubeshkin, Alexey A. Schulga, Elena V. Konovalova, Quan Lin, Indrajit Roy, Irina V. Balalaeva, Sergey M. Deyev, Andrei V.
    Molecules.2020; 25(18): 4302.     CrossRef
  • Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer
    Min Chong Kim, Su Hwan Kang, Jung Eun Choi, Young Kyung Bae
    Journal of Breast Cancer.2020; 23(5): 484.     CrossRef
Good Laboratory Standards for Clinical Next-Generation Sequencing Cancer Panel Tests
Jihun Kim, Woong-Yang Park, Nayoung K. D. Kim, Se Jin Jang, Sung-Min Chun, Chang-Ohk Sung, Jene Choi, Young-Hyeh Ko, Yoon-La Choi, Hyo Sup Shim, Jae-Kyung Won
J Pathol Transl Med. 2017;51(3):191-204.   Published online May 10, 2017
DOI: https://doi.org/10.4132/jptm.2017.03.14
  • 23,607 View
  • 1,077 Download
  • 32 Web of Science
  • 33 Crossref
AbstractAbstract PDF
Next-generation sequencing (NGS) has recently emerged as an essential component of personalized cancer medicine due to its high throughput and low per-base cost. However, no sufficient guidelines for implementing NGS as a clinical molecular pathology test are established in Korea. To ensure clinical grade quality without inhibiting adoption of NGS, a taskforce team assembled by the Korean Society of Pathologists developed laboratory guidelines for NGS cancer panel testing procedures and requirements for clinical implementation of NGS. This consensus standard proposal consists of two parts: laboratory guidelines and requirements for clinical NGS laboratories. The laboratory guidelines part addressed several important issues across multistep NGS cancer panel tests including choice of gene panel and platform, sample handling, nucleic acid management, sample identity tracking, library preparation, sequencing, analysis and reporting. Requirements for clinical NGS tests were summarized in terms of documentation, validation, quality management, and other required written policies. Together with appropriate pathologist training and international laboratory standards, these laboratory standards would help molecular pathology laboratories to successfully implement NGS cancer panel tests in clinic. In this way, the oncology community would be able to help patients to benefit more from personalized cancer medicine.

Citations

Citations to this article as recorded by  
  • Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II
    Sun Young Kim, Jee Hyun Kim, Tae-Yong Kim, Sook Ryun Park, Shinkyo Yoon, Soohyeon Lee, Se-Hoon Lee, Tae Min Kim, Sae-Won Han, Hye Ryun Kim, Hongseok Yun, Sejoon Lee, Jihun Kim, Yoon-La Choi, Kui Son Choi, Heejung Chae, Hyewon Ryu, Gyeong-Won Lee, Dae Youn
    BMC Cancer.2024;[Epub]     CrossRef
  • Reporting of somatic variants in clinical cancer care: recommendations of the Swiss Society of Molecular Pathology
    Yann Christinat, Baptiste Hamelin, Ilaria Alborelli, Paolo Angelino, Valérie Barbié, Bettina Bisig, Heather Dawson, Milo Frattini, Tobias Grob, Wolfram Jochum, Ronny Nienhold, Thomas McKee, Matthias Matter, Edoardo Missiaglia, Francesca Molinari, Sacha Ro
    Virchows Archiv.2024;[Epub]     CrossRef
  • Validation and Clinical Application of ONCOaccuPanel for Targeted Next-Generation Sequencing of Solid Tumors
    Moonsik Kim, Changseon Lee, Juyeon Hong, Juhee Kim, Ji Yun Jeong, Nora Jee-Young Park, Ji-Eun Kim, Ji Young Park
    Cancer Research and Treatment.2023; 55(2): 429.     CrossRef
  • Establishing molecular pathology curriculum for pathology trainees and continued medical education: a collaborative work from the Molecular Pathology Study Group of the Korean Society of Pathologists
    Jiwon Koh, Ha Young Park, Jeong Mo Bae, Jun Kang, Uiju Cho, Seung Eun Lee, Haeyoun Kang, Min Eui Hong, Jae Kyung Won, Youn-La Choi, Wan-Seop Kim, Ahwon Lee
    Journal of Pathology and Translational Medicine.2023; 57(5): 265.     CrossRef
  • Clinical applications of next-generation sequencing in the diagnosis of genetic disorders in Korea: a narrative review
    Jihoon G. Yoon, Man Jin Kim, Yong Jin Kwon, Jong-Hee Chae
    Journal of the Korean Medical Association.2023; 66(10): 613.     CrossRef
  • Obtaining spatially resolved tumor purity maps using deep multiple instance learning in a pan-cancer study
    Mustafa Umit Oner, Jianbin Chen, Egor Revkov, Anne James, Seow Ye Heng, Arife Neslihan Kaya, Jacob Josiah Santiago Alvarez, Angela Takano, Xin Min Cheng, Tony Kiat Hon Lim, Daniel Shao Weng Tan, Weiwei Zhai, Anders Jacobsen Skanderup, Wing-Kin Sung, Hwee
    Patterns.2022; 3(2): 100399.     CrossRef
  • Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine
    Ka-Hei (Murphy) Sun, Yin-Ting (Heylie) Wong, Ka-Man (Carmen) Cheung, Carmen (Michelle) Yuen, Yun-Tat (Ted) Chan, Wing-Yan (Jennifer) Lai, Chun (David) Chao, Wing-Sum (Katie) Fan, Yuen-Kiu (Karen) Chow, Man-Fai Law, Ho-Chi (Tommy) Tam
    Diagnostics.2022; 12(2): 409.     CrossRef
  • Defining Novel DNA Virus-Tumor Associations and Genomic Correlates Using Prospective Clinical Tumor/Normal Matched Sequencing Data
    Chad M. Vanderbilt, Anita S. Bowman, Sumit Middha, Kseniya Petrova-Drus, Yi-Wei Tang, Xin Chen, Youxiang Wang, Jason Chang, Natasha Rekhtman, Klaus J. Busam, Sounak Gupta, Meera Hameed, Maria E. Arcila, Marc Ladanyi, Michael F. Berger, Snjezana Dogan, Ahm
    The Journal of Molecular Diagnostics.2022; 24(5): 515.     CrossRef
  • Performance Evaluation of Three DNA Sample Tracking Tools in a Whole Exome Sequencing Workflow
    Gertjan Wils, Céline Helsmoortel, Pieter-Jan Volders, Inge Vereecke, Mauro Milazzo, Jo Vandesompele, Frauke Coppieters, Kim De Leeneer, Steve Lefever
    Molecular Diagnosis & Therapy.2022; 26(4): 411.     CrossRef
  • Clinical Quality Considerations when Using Next-Generation Sequencing (NGS) in Clinical Drug Development
    Timothé Ménard, Alaina Barros, Christopher Ganter
    Therapeutic Innovation & Regulatory Science.2021; 55(5): 1066.     CrossRef
  • Fast Healthcare Interoperability Resources (FHIR)–Based Quality Information Exchange for Clinical Next-Generation Sequencing Genomic Testing: Implementation Study
    Donghyeong Seong, Sungwon Jung, Sungchul Bae, Jongsuk Chung, Dae-Soon Son, Byoung-Kee Yi
    Journal of Medical Internet Research.2021; 23(4): e26261.     CrossRef
  • Status of Next-Generation Sequencing-Based Genetic Diagnosis in Hematologic Malignancies in Korea (2017-2018)
    JinJu Kim, Ja Young Lee, Jungwon Huh, Myung-Hyun Nam, Myungshin Kim, Young-Uk Cho, Sun-Young Kong, Seung-Tae Lee, In-Suk Kim
    Laboratory Medicine Online.2021; 11(1): 25.     CrossRef
  • MSI-Testung
    Josef Rüschoff, Gustavo Baretton, Hendrik Bläker, Wolfgang Dietmaier, Manfred Dietel, Arndt Hartmann, Lars-Christian Horn, Korinna Jöhrens, Thomas Kirchner, Ruth Knüchel, Doris Mayr, Sabine Merkelbach-Bruse, Hans-Ulrich Schildhaus, Peter Schirmacher, Mark
    Der Pathologe.2021; 42(4): 414.     CrossRef
  • Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
    Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
    Journal of Pathology and Translational Medicine.2021; 55(3): 181.     CrossRef
  • MSI testing
    Josef Rüschoff, Gustavo Baretton, Hendrik Bläker, Wolfgang Dietmaier, Manfred Dietel, Arndt Hartmann, Lars-Christian Horn, Korinna Jöhrens, Thomas Kirchner, Ruth Knüchel, Doris Mayr, Sabine Merkelbach-Bruse, Hans-Ulrich Schildhaus, Peter Schirmacher, Mark
    Der Pathologe.2021; 42(S1): 110.     CrossRef
  • 16S rDNA microbiome composition pattern analysis as a diagnostic biomarker for biliary tract cancer
    Huisong Lee, Hyeon Kook Lee, Seog Ki Min, Won Hee Lee
    World Journal of Surgical Oncology.2020;[Epub]     CrossRef
  • Risk Stratification Using a Novel Genetic Classifier IncludingPLEKHS1Promoter Mutations for Differentiated Thyroid Cancer with Distant Metastasis
    Chan Kwon Jung, Seung-Hyun Jung, Sora Jeon, Young Mun Jeong, Yourha Kim, Sohee Lee, Ja-Seong Bae, Yeun-Jun Chung
    Thyroid.2020; 30(11): 1589.     CrossRef
  • Biomarker testing for advanced lung cancer by next-generation sequencing; a valid method to achieve a comprehensive glimpse at mutational landscape
    Anurag Mehta, Smreti Vasudevan, Sanjeev Kumar Sharma, Manoj Panigrahi, Moushumi Suryavanshi, Mumtaz Saifi, Ullas Batra
    Applied Cancer Research.2020;[Epub]     CrossRef
  • Application Areas of Traditional Molecular Genetic Methods and NGS in relation to Hereditary Urological Cancer Diagnosis
    Dmitry S. Mikhaylenko, Alexander S. Tanas, Dmitry V. Zaletaev, Marina V. Nemtsova
    Journal of Oncology.2020; 2020: 1.     CrossRef
  • Assembling and Validating Bioinformatic Pipelines for Next-Generation Sequencing Clinical Assays
    Jeffrey A SoRelle, Megan Wachsmann, Brandi L. Cantarel
    Archives of Pathology & Laboratory Medicine.2020; 144(9): 1118.     CrossRef
  • Standard operating procedure for somatic variant refinement of sequencing data with paired tumor and normal samples
    Erica K. Barnell, Peter Ronning, Katie M. Campbell, Kilannin Krysiak, Benjamin J. Ainscough, Lana M. Sheta, Shahil P. Pema, Alina D. Schmidt, Megan Richters, Kelsy C. Cotto, Arpad M. Danos, Cody Ramirez, Zachary L. Skidmore, Nicholas C. Spies, Jasreet Hun
    Genetics in Medicine.2019; 21(4): 972.     CrossRef
  • A DNA pool of FLT3-ITD positive DNA samples can be used efficiently for analytical evaluation of NGS-based FLT3-ITD quantitation - Testing several different ITD sequences and rates, simultaneously
    Zoltán A. Mezei, Dávid Tornai, Róza Földesi, László Madar, Andrea Sümegi, Mária Papp, Péter Antal-Szalmás
    Journal of Biotechnology.2019; 303: 25.     CrossRef
  • Pharmacogenomic Testing: Clinical Evidence and Implementation Challenges
    Catriona Hippman, Corey Nislow
    Journal of Personalized Medicine.2019; 9(3): 40.     CrossRef
  • Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study
    Dohee Kwon, Binnari Kim, Hyeong Chan Shin, Eun Ji Kim, Sang Yun Ha, Kee-Taek Jang, Seung Tae Kim, Jeeyun Lee, Won Ki Kang, Joon Oh Park, Kyoung-Mee Kim
    Translational Oncology.2019; 12(11): 1488.     CrossRef
  • Analytical Evaluation of an NGS Testing Method for Routine Molecular Diagnostics on Melanoma Formalin-Fixed, Paraffin-Embedded Tumor-Derived DNA
    Irene Mancini, Lisa Simi, Francesca Salvianti, Francesca Castiglione, Gemma Sonnati, Pamela Pinzani
    Diagnostics.2019; 9(3): 117.     CrossRef
  • Benchmark Database for Process Optimization and Quality Control of Clinical Cancer Panel Sequencing
    Donghyeong Seong, Jongsuk Chung, Ki-Wook Lee, Sook-Young Kim, Byung-Suk Kim, Jung-Keun Song, Sungwon Jung, Taeseob Lee, Donghyun Park, Byoung-Kee Yi, Woong-Yang Park, Dae-Soon Son
    Biotechnology and Bioprocess Engineering.2019; 24(5): 793.     CrossRef
  • Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients
    Simon Heeke, Véronique Hofman, Elodie Long-Mira, Virginie Lespinet, Salomé Lalvée, Olivier Bordone, Camille Ribeyre, Virginie Tanga, Jonathan Benzaquen, Sylvie Leroy, Charlotte Cohen, Jérôme Mouroux, Charles Marquette, Marius Ilié, Paul Hofman
    Cancers.2018; 10(4): 88.     CrossRef
  • Use of the Ion AmpliSeq Cancer Hotspot Panel in clinical molecular pathology laboratories for analysis of solid tumours: With emphasis on validation with relevant single molecular pathology tests and the Oncomine Focus Assay
    Ahwon Lee, Sung-Hak Lee, Chan Kwon Jung, Gyungsin Park, Kyo Young Lee, Hyun Joo Choi, Ki Ouk Min, Tae Jung Kim, Eun Jung Lee, Youn Soo Lee
    Pathology - Research and Practice.2018; 214(5): 713.     CrossRef
  • Recent Advancement of the Molecular Diagnosis in Pediatric Brain Tumor
    Jeong-Mo Bae, Jae-Kyung Won, Sung-Hye Park
    Journal of Korean Neurosurgical Society.2018; 61(3): 376.     CrossRef
  • The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics
    Caterina Fumagalli, Davide Vacirca, Alessandra Rappa, Antonio Passaro, Juliana Guarize, Paola Rafaniello Raviele, Filippo de Marinis, Lorenzo Spaggiari, Chiara Casadio, Giuseppe Viale, Massimo Barberis, Elena Guerini-Rocco
    Journal of Clinical Pathology.2018; 71(9): 767.     CrossRef
  • Clinical laboratory utilization management and improved healthcare performance
    Christopher Naugler, Deirdre L. Church
    Critical Reviews in Clinical Laboratory Sciences.2018; 55(8): 535.     CrossRef
  • Development of HLA-A, -B and -DR Typing Method Using Next-Generation Sequencing
    Dong Hee Seo, Jeong Min Lee, Mi Ok Park, Hyun Ju Lee, Seo Yoon Moon, Mijin Oh, So Young Kim, Sang-Heon Lee, Ki-Eun Hyeong, Hae-Jin Hu, Dae-Yeon Cho
    The Korean Journal of Blood Transfusion.2018; 29(3): 310.     CrossRef
  • Value-based genomics
    Jun Gong, Kathy Pan, Marwan Fakih, Sumanta Pal, Ravi Salgia
    Oncotarget.2018; 9(21): 15792.     CrossRef
Molecular Testing of Lung Cancers
Hyo Sup Shim, Yoon-La Choi, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Mee Sook Roh, Tae-Jung Kim, Seung Yeon Ha, Jin-Haeng Chung, Se Jin Jang, Geon Kook Lee
J Pathol Transl Med. 2017;51(3):242-254.   Published online April 21, 2017
DOI: https://doi.org/10.4132/jptm.2017.04.10
  • 14,537 View
  • 598 Download
  • 26 Web of Science
  • 26 Crossref
AbstractAbstract PDF
Targeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively. Besides EGFR and ALK, the list of druggable genetic alterations has been growing, including ROS1 rearrangements, RET rearrangements, and MET alterations. In this situation, pathologists should carefully manage clinical samples for molecular testing and should do their best to quickly and accurately identify patients who will benefit from precision therapeutics. Here, we grouped molecular biomarkers of lung cancers into three categories—mutations, gene rearrangements, and amplifications—and propose expanded guidelines on molecular testing of lung cancers.

Citations

Citations to this article as recorded by  
  • Enhancing Lung Cancer Care in Portugal: Bridging Gaps for Improved Patient Outcomes
    Raquel Ramos, Conceição Souto Moura, Mariana Costa, Nuno Jorge Lamas, Renato Correia, Diogo Garcez, José Miguel Pereira, Carlos Sousa, Nuno Vale
    Journal of Personalized Medicine.2024; 14(5): 446.     CrossRef
  • Evolution of therapy for ALK-positive lung carcinomas: Application of third-generation ALK inhibitors in real clinical practice
    A. F. Nasretdinov, A. V. Sultanbaev, Sh. I. Musin, K. V. Menshikov, R. T. Ayupov, A. A. Izmailov, G. A. Serebrennikov, V. E. Askarov, D. V. Feoktistov
    Meditsinskiy sovet = Medical Council.2024; (10): 74.     CrossRef
  • Cost-effectiveness of next-generation sequencing for advanced EGFR/ALK-negative non-small cell lung cancer
    Dong-Won Kang, Sun-Kyeong Park, Sokbom Kang, Eui-Kyung Lee
    Lung Cancer.2024; 197: 107970.     CrossRef
  • miR-92a-3p regulates cisplatin-induced cancer cell death
    Romain Larrue, Sandy Fellah, Nihad Boukrout, Corentin De Sousa, Julie Lemaire, Carolane Leboeuf, Marine Goujon, Michael Perrais, Bernard Mari, Christelle Cauffiez, Nicolas Pottier, Cynthia Van der Hauwaert
    Cell Death & Disease.2023;[Epub]     CrossRef
  • Diagnostic Approach of Lung Cancer: A Literature Review
    Jesi Hana, Novia Nurul Faizah
    Jurnal Respirasi.2023; 9(2): 141.     CrossRef
  • Molecular Pathology of Lung Cancer
    James J. Saller, Theresa A. Boyle
    Cold Spring Harbor Perspectives in Medicine.2022; 12(3): a037812.     CrossRef
  • Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
    Jeonghyo Lee, Yeon Bi Han, Hyun Jung Kwon, Song Kook Lee, Hyojin Kim, Jin-Haeng Chung
    Journal of Pathology and Translational Medicine.2022; 56(5): 249.     CrossRef
  • Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
    Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
    Journal of Pathology and Translational Medicine.2021; 55(3): 181.     CrossRef
  • TM4SF4 and LRRK2 Are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis
    Kyungsoo Jung, Joon-Seok Choi, Beom-Mo Koo, Yu Jin Kim, Ji-Young Song, Minjung Sung, Eun Sol Chang, Ka-Won Noh, Sungbin An, Mi-Sook Lee, Kyoung Song, Hannah Lee, Ryong Nam Kim, Young Kee Shin, Doo-Yi Oh, Yoon-La Choi
    Cancer Research and Treatment.2021; 53(1): 9.     CrossRef
  • The promises and challenges of early non‐small cell lung cancer detection: patient perceptions, low‐dose CT screening, bronchoscopy and biomarkers
    Lukas Kalinke, Ricky Thakrar, Sam M. Janes
    Molecular Oncology.2021; 15(10): 2544.     CrossRef
  • Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review
    Anthony Yu, Eva Huang, Momoka Abe, Kang An, Sun-Kyeong Park, Chanhyun Park
    Expert Review of Pharmacoeconomics & Outcomes Research.2021; 21(3): 381.     CrossRef
  • The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC
    Parth Shah, Jacob Sands, Nicola Normanno
    Lung Cancer.2021; 160: 118.     CrossRef
  • Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets
    Mercedes L Dalurzo, Alejandro Avilés-Salas, Fernando Augusto Soares, Yingyong Hou, Yuan Li, Anna Stroganova, Büge Öz, Arif Abdillah, Hui Wan, Yoon-La Choi
    OncoTargets and Therapy.2021; Volume 14: 4671.     CrossRef
  • Treatment of Patients With Non–Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations
    Melina E. Marmarelis, Corey J. Langer
    Clinical Lung Cancer.2020; 21(5): 395.     CrossRef
  • Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing
    Eunhyang Park, Hyo Sup Shim
    Cancer Research and Treatment.2020; 52(2): 543.     CrossRef
  • High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma
    Yuyin Xu, Heng Chang, Lijing Wu, Xin Zhang, Ling Zhang, Jing Zhang, Yuan Li, Lei Shen, Xiaoli Zhu, Xiaoyan Zhou, Qianming Bai
    Experimental and Molecular Pathology.2020; 117: 104548.     CrossRef
  • An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients
    Jiacong Wei, Anna A. Rybczynska, Pei Meng, Martijn Terpstra, Ali Saber, Jantine Sietzema, Wim Timens, Ed Schuuring, T. Jeroen N. Hiltermann, Harry. J.M. Groen, Anthonie van der Wekken, Anke van den Berg, Klaas Kok
    Cancers.2020; 12(10): 2843.     CrossRef
  • Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer
    Alexander Gavralidis, Justin F. Gainor
    The Cancer Journal.2020; 26(6): 517.     CrossRef
  • Role of Immunocytochemistry in the Cytological Diagnosis of Pulmonary Tumors
    Jasna Metovic, Luisella Righi, Luisa Delsedime, Marco Volante, Mauro Papotti
    Acta Cytologica.2020; 64(1-2): 16.     CrossRef
  • Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer
    Eun Kyung Kim, Kyung A. Kim, Chang Young Lee, Sangwoo Kim, Sunhee Chang, Byoung Chul Cho, Hyo Sup Shim
    Clinical Lung Cancer.2019; 20(1): e123.     CrossRef
  • PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
    Jongmin Lee, Chan Kwon Park, Hyoung‐Kyu Yoon, Young Jo Sa, In Sook Woo, Hyo Rim Kim, Sue Youn Kim, Tae‐Jung Kim
    Thoracic Cancer.2019; 10(1): 103.     CrossRef
  • Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung
    Yeon Bi Han, Hyun Jung Kwon, Soo Young Park, Eun-Sun Kim, Hyojin Kim, Jin-Haeng Chung
    Journal of Pathology and Translational Medicine.2019; 53(2): 86.     CrossRef
  • Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society
    Pathmanathan Rajadurai, Phaik Leng Cheah, Soon Hin How, Chong Kin Liam, Muhammad Azrif Ahmad Annuar, Norhayati Omar, Noriah Othman, Nurhayati Mohd Marzuki, Yong Kek Pang, Ros Suzanna Ahmad Bustamam, Lye Mun Tho
    Lung Cancer.2019; 136: 65.     CrossRef
  • Somatic mutations and immune checkpoint biomarkers
    Brielle A. Parris, Eloise Shaw, Brendan Pang, Richie Soong, Kwun Fong, Ross A. Soo
    Respirology.2019; 24(3): 215.     CrossRef
  • Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib
    Anna Chalmers, Laura Cannon, Wallace Akerley
    The Oncologist.2019; 24(7): 963.     CrossRef
  • Genetic and clinicopathologic characteristics of lung adenocarcinoma with tumor spread through air spaces
    Jae Seok Lee, Eun Kyung Kim, Moonsik Kim, Hyo Sup Shim
    Lung Cancer.2018; 123: 121.     CrossRef
Pathology Reporting of Thyroid Core Needle Biopsy: A Proposal of the Korean Endocrine Pathology Thyroid Core Needle Biopsy Study Group
Chan Kwon Jung, Hye Sook Min, Hyo Jin Park, Dong Eun Song, Jang Hee Kim, So Yeon Park, Hyunju Yoo, Mi Kyung Shin, Korean Endocrine Pathology Thyroid Core Needle Biopsy Study Group
J Pathol Transl Med. 2015;49(4):288-299.   Published online June 17, 2015
DOI: https://doi.org/10.4132/jptm.2015.06.04
  • 17,116 View
  • 434 Download
  • 103 Web of Science
  • 98 Crossref
AbstractAbstract PDF
In recent years throughout Korea, the use of ultrasound-guided core needle biopsy (CNB) has become common for the preoperative diagnosis of thyroid nodules. However, there is no consensus on the pathology reporting system for thyroid CNB. The Korean Endocrine Pathology Thyroid Core Needle Biopsy Study Group held a conference on thyroid CNB pathology and developed guidelines through contributions from the participants. This article discusses the outcome of the discussions that led to a consensus on the pathology reporting of thyroid CNB.

Citations

Citations to this article as recorded by  
  • The Diagnostic Role of Repeated Biopsy of Thyroid Nodules with Atypia of Undetermined Significance with Architectural Atypia on Core-Needle Biopsy
    Hye Hyeon Moon, Sae Rom Chung, Young Jun Choi, Tae-Yon Sung, Dong Eun Song, Tae Yong Kim, Jeong Hyun Lee, Jung Hwan Baek
    Endocrinology and Metabolism.2024; 39(2): 300.     CrossRef
  • Core needle biopsy for thyroid nodules assessment-a new horizon?
    David D Dolidze, Serghei Covantsev, Grigorii M Chechenin, Natalia V Pichugina, Anastasia V Bedina, Anna Bumbu
    World Journal of Clinical Oncology.2024; 15(5): 580.     CrossRef
  • Ultrasonographic features and diagnostic accuracy of FNA and CNB in secondary thyroid malignancies: A retrospective study
    Zhen Xia, Xiaochen Huang, Ting Zhang, Zhigang Gao, Xiuliang Tang, Wei Zhang, Qing Miao
    Heliyon.2024; 10(16): e36305.     CrossRef
  • Current role of interventional radiology in thyroid nodules
    Onur Taydas, Erbil Arik, Omer Faruk Sevinc, Ahmet Burak Kara, Mustafa Ozdemir, Hasret Cengiz, Zulfu Bayhan, Mehmet Halil Ozturk
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Follow-up of benign thyroid nodules confirmed by ultrasound-guided core needle biopsy after inconclusive cytology on fine-needle aspiration biopsy
    Yoon Ji Hwang, Hye Ryoung Koo, Jeong Seon Park
    Ultrasonography.2023; 42(1): 121.     CrossRef
  • Subcategorization of intermediate suspicion thyroid nodules based on suspicious ultrasonographic findings
    Haejung Kim, Jung Hee Shin, Ka Eun Kim, Myoung Kyoung Kim, Jiyun Oh, Soo Yeon Hahn
    Ultrasonography.2023; 42(2): 307.     CrossRef
  • Preoperative Risk Stratification of Follicular-patterned Thyroid Lesions on Core Needle Biopsy by Histologic Subtyping and RAS Variant-specific Immunohistochemistry
    Meejeong Kim, Sora Jeon, Chan Kwon Jung
    Endocrine Pathology.2023; 34(2): 247.     CrossRef
  • Cytological and Ultrasound Features of Thyroid Nodules Correlate With Histotypes and Variants of Thyroid Carcinoma
    Daniele Sgrò, Alessandro Brancatella, Giuseppe Greco, Liborio Torregrossa, Paolo Piaggi, Nicola Viola, Teresa Rago, Fulvio Basolo, Riccardo Giannini, Gabriele Materazzi, Rossella Elisei, Ferruccio Santini, Francesco Latrofa
    The Journal of Clinical Endocrinology & Metabolism.2023; 108(11): e1186.     CrossRef
  • Reevaluating diagnostic categories and associated malignancy risks in thyroid core needle biopsy
    Chan Kwon Jung
    Journal of Pathology and Translational Medicine.2023; 57(4): 208.     CrossRef
  • Contrast Enhancement Ultrasound Improves Diagnostic Accuracy for Thyroid Nodules: A Prospective Multicenter Study
    Jianming Li, Jianping Dou, Huarong Li, Fan Xiao, Jie Yu, Mingxing Xie, Ping Zhou, Lei Liang, Guiming Zhou, Ying Che, Cun Liu, Zhibin Cong, Fangyi Liu, Zhiyu Han, Ping Liang
    Journal of the Endocrine Society.2023;[Epub]     CrossRef
  • Core needle biopsy and ultrasonography are superior to fine needle aspiration in the management of follicular variant papillary thyroid carcinomas
    Ji-Ye Kim, Sunhee Chang, Ah-Young Kwon, Eun Young Park, Tae Hyuk Kim, Sangjoon Choi, Minju Lee, Young Lyun Oh
    Endocrine.2022; 75(2): 437.     CrossRef
  • Fine Needle Aspiration Cytology vs. Core Needle Biopsy for Thyroid Nodules: A Prospective, Experimental Study Using Surgical Specimen
    Hyuk Kwon, Jandee Lee, Soon Won Hong, Hyeong Ju Kwon, Jin Young Kwak, Jung Hyun Yoon
    Journal of the Korean Society of Radiology.2022; 83(3): 645.     CrossRef
  • Diagnostic efficacy, performance and safety of side-cut core needle biopsy for thyroid nodules: comparison of automated and semi-automated biopsy needles
    Ji Yeon Park, Seong Yoon Yi, Soo Heui Baek, Yu Hyun Lee, Heon-Ju Kwon, Hee Jin Park
    Endocrine.2022; 76(2): 341.     CrossRef
  • Approach to Bethesda system category III thyroid nodules according to US-risk stratification
    Jieun Kim, Jung Hee Shin, Young Lyun Oh, Soo Yeon Hahn, Ko Woon Park
    Endocrine Journal.2022; 69(1): 67.     CrossRef
  • Quantitative analysis of vascularity for thyroid nodules on ultrasound using superb microvascular imaging
    Min Ji Hong, Hye Shin Ahn, Su Min Ha, Hyun Jeong Park, Jiyun Oh
    Medicine.2022; 101(5): e28725.     CrossRef
  • Diagnostic Performance of Thyroid Core Needle Biopsy Using the Revised Reporting System: Comparison with Fine Needle Aspiration Cytology
    Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim, So Lyung Jung, Chan Kwon Jung
    Endocrinology and Metabolism.2022; 37(1): 159.     CrossRef
  • A Matched-Pair Analysis of Nuclear Morphologic Features Between Core Needle Biopsy and Surgical Specimen in Thyroid Tumors Using a Deep Learning Model
    Faridul Haq, Andrey Bychkov, Chan Kwon Jung
    Endocrine Pathology.2022; 33(4): 472.     CrossRef
  • Role of echogenic foci in ultrasonographic risk stratification of thyroid nodules: Echogenic focus scoring in the American College of Radiology Thyroid Imaging Reporting and Data System
    Renxu Li, Zhenwei Liang, Xiangyu Wang, Luzeng Chen
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Ultrasonographic characteristics of medullary thyroid carcinoma according to nodule size: application of the Korean Thyroid Imaging Reporting and Data System and American Thyroid Association guidelines
    Soo Yeon Hahn, Jung Hee Shin, Young Lyun Oh, Ko Woon Park
    Acta Radiologica.2021; 62(4): 474.     CrossRef
  • Malignancy risk of thyroid nodules with nonshadowing echogenic foci
    Yu-Mee Sohn, Dong Gyu Na, Wooyul Paik, Hye Yun Gwon, Byeong-Joo Noh
    Ultrasonography.2021; 40(1): 115.     CrossRef
  • Assessing the diagnostic performance of thyroid biopsy with recommendations for appropriate interpretation
    Su Min Ha, Jung Hwan Baek, Dong Gyu Na, Chan-Kwon Jung, Chong Hyun Suh, Young Kee Shong, Tae Yon Sung, Dong Eun Song, Jeong Hyun Lee
    Ultrasonography.2021; 40(2): 228.     CrossRef
  • Usage and Diagnostic Yield of Fine-Needle Aspiration Cytology and Core Needle Biopsy in Thyroid Nodules: A Systematic Review and Meta-Analysis of Literature Published by Korean Authors
    Soon-Hyun Ahn
    Clinical and Experimental Otorhinolaryngology.2021; 14(1): 116.     CrossRef
  • Comparison of the Efficacy and Safety of the American Thyroid Association Guidelines and American College of Radiology TI-RADS
    Jinghua Liu, Yajun Guo, Jiangxi Xiao, Luzeng Chen, Zhenwei Liang
    Endocrine Practice.2021; 27(7): 661.     CrossRef
  • Malignancy Rate of Bethesda Class III Thyroid Nodules Based on the Presence of Chronic Lymphocytic Thyroiditis in Surgical Patients
    Yoon Young Cho, Yun Jae Chung, Hee Sung Kim
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Efficacy of Differential Diagnosis of Thyroid Nodules by Shear Wave Elastography—the Stiffness Map
    Myung Hi Yoo, Hye Jeong Kim, In Ho Choi, Suyeon Park, Sumi Yun, Hyeong Kyu Park, Dong Won Byun, Kyoil Suh
    Journal of the Endocrine Society.2021;[Epub]     CrossRef
  • The relationship of thyroid nodule size on malignancy risk according to histological type of thyroid cancer
    Sae Rom Chung, Jung Hwan Baek, Young Jun Choi, Tae-Yon Sung, Dong Eun Song, Tae Yong Kim, Jeong Hyun Lee
    Acta Radiologica.2020; 61(5): 620.     CrossRef
  • Concordance of Three International Guidelines for Thyroid Nodules Classified by Ultrasonography and Diagnostic Performance of Biopsy Criteria
    Younghee Yim, Dong Gyu Na, Eun Ju Ha, Jung Hwan Baek, Jin Yong Sung, Ji-hoon Kim, Won-Jin Moon
    Korean Journal of Radiology.2020; 21(1): 108.     CrossRef
  • 2019 Practice guidelines for thyroid core needle biopsy: a report of the Clinical Practice Guidelines Development Committee of the Korean Thyroid Association
    Chan Kwon Jung, Jung Hwan Baek, Dong Gyu Na, Young Lyun Oh, Ka Hee Yi, Ho-Cheol Kang
    Journal of Pathology and Translational Medicine.2020; 54(1): 64.     CrossRef
  • Core-Needle Biopsy Does Not Show Superior Diagnostic Performance to Fine-Needle Aspiration for Diagnosing Thyroid Nodules
    Ilah Shin, Eun-Kyung Kim, Hee Jung Moon, Jung Hyun Yoon, Vivian Youngjean Park, Si Eun Lee, Hye Sun Lee, Jin Young Kwak
    Yonsei Medical Journal.2020; 61(2): 161.     CrossRef
  • Ultrasound‐guided fine‐needle aspiration or core needle biopsy for diagnosing follicular thyroid carcinoma?
    Ko Woon Park, Jung Hee Shin, Soo Yeon Hahn, Young Lyun Oh, Sun Wook Kim, Tae Hyuk Kim, Jae Hoon Chung
    Clinical Endocrinology.2020; 92(5): 468.     CrossRef
  • Distribution and malignancy risk of six categories of the pathology reporting system for thyroid core-needle biopsy in 1,216 consecutive thyroid nodules
    Hye Min Son, Ji-hoon Kim, Soo Chin Kim, Roh-Eul Yoo, Jeong Mo Bae, Hyobin Seo, Dong Gyu Na
    Ultrasonography.2020; 39(2): 159.     CrossRef
  • CT features of thyroid nodules with isolated macrocalcifications detected by ultrasonography
    Wooyul Paik, Dong Gyu Na, Hye Yun Gwon, Jinna Kim
    Ultrasonography.2020; 39(2): 130.     CrossRef
  • Contribution of cytologic examination to diagnosis of poorly differentiated thyroid carcinoma
    Na Rae Kim, Jae Yeon Seok, Yoo Seung Chung, Joon Hyop Lee, Dong Hae Chung
    Journal of Pathology and Translational Medicine.2020; 54(2): 171.     CrossRef
  • Comparison Between Fine Needle Aspiration and Core Needle Biopsy for the Diagnosis of Thyroid Nodules: Effective Indications According to US Findings
    Soo Yeon Hahn, Jung Hee Shin, Young Lyun Oh, Ko Woon Park, Yaeji Lim
    Scientific Reports.2020;[Epub]     CrossRef
  • Thyroid Nodules with Isolated Macrocalcifications: Malignancy Risk of Isolated Macrocalcifications and Postoperative Risk Stratification of Malignant Tumors Manifesting as Isolated Macrocalcifications
    Hye Yun Gwon, Dong Gyu Na, Byeong-Joo Noh, Wooyul Paik, So Jin Yoon, Soo-Jung Choi, Dong Rock Shin
    Korean Journal of Radiology.2020; 21(5): 605.     CrossRef
  • Diagnostic Efficacy and Safety of Core Needle Biopsy as a First-Line Diagnostic Method for Thyroid Nodules: A Prospective Cohort Study
    Min Ji Hong, Dong Gyu Na, Hunkyung Lee
    Thyroid.2020; 30(8): 1141.     CrossRef
  • Re: The 2019 core-needle biopsy practice guidelines
    Ji-hoon Kim
    Ultrasonography.2020; 39(3): 313.     CrossRef
  • Cytopathologic criteria and size should be considered in comparison of fine-needle aspiration vs. core-needle biopsy for thyroid nodules: results based on large surgical series
    Jung Hyun Yoon, Hye Sun Lee, Eun-Kyung Kim, Hee Jung Moon, Vivian Youngjean Park, Jin Young Kwak
    Endocrine.2020; 70(3): 558.     CrossRef
  • Preoperative diagnostic categories of fine needle aspiration cytology for histologically proven thyroid follicular adenoma and carcinoma, and Hurthle cell adenoma and carcinoma: Analysis of cause of under- or misdiagnoses
    Hee Young Na, Jae Hoon Moon, June Young Choi, Hyeong Won Yu, Woo-Jin Jeong, Yeo Koon Kim, Ji-Young Choe, So Yeon Park, Paula Soares
    PLOS ONE.2020; 15(11): e0241597.     CrossRef
  • The Role of Core Needle Biopsy for the Evaluation of Thyroid Nodules with Suspicious Ultrasound Features
    Sae Rom Chung, Jung Hwan Baek, Young Jun Choi, Tae-Yon Sung, Dong Eun Song, Tae Yong Kim, Jeong Hyun Lee
    Korean Journal of Radiology.2019; 20(1): 158.     CrossRef
  • Pathological diagnosis of thyroid nodules based on core needle biopsies: comparative study between core needle biopsies and resected specimens in 578 cases
    Yan Xiong, Limin Yan, Lin Nong, Yalin Zheng, Ting Li
    Diagnostic Pathology.2019;[Epub]     CrossRef
  • The Current Histologic Classification of Thyroid Cancer
    Sylvia L. Asa
    Endocrinology and Metabolism Clinics of North America.2019; 48(1): 1.     CrossRef
  • Core-needle biopsy in thyroid nodules: performance, accuracy, and complications
    Miguel Paja, Jose Luis del Cura, Rosa Zabala, Igone Korta, Aitziber Ugalde, José I. López
    European Radiology.2019; 29(9): 4889.     CrossRef
  • Ultrasound‐guided needle biopsy of large thyroid nodules: Core needle biopsy yields more reliable results than fine needle aspiration
    Hyeon Jin Lee, Young Joong Kim, Hye Yeon Han, Jae Young Seo, Cheol Mog Hwang, KeumWon Kim
    Journal of Clinical Ultrasound.2019; 47(5): 255.     CrossRef
  • Tumor Volume Doubling Time in Active Surveillance of Papillary Thyroid Carcinoma
    Hye-Seon Oh, Hyemi Kwon, Eyun Song, Min Ji Jeon, Tae Yong Kim, Jeong Hyun Lee, Won Bae Kim, Young Kee Shong, Ki-Wook Chung, Jung Hwan Baek, Won Gu Kim
    Thyroid.2019; 29(5): 642.     CrossRef
  • Role of Immunohistochemistry in Fine Needle Aspiration and Core Needle Biopsy of Thyroid Nodules
    Seulki Song, Hyojin Kim, Soon-Hyun Ahn
    Clinical and Experimental Otorhinolaryngology.2019; 12(2): 224.     CrossRef
  • Echogenic foci in thyroid nodules: diagnostic performance with combination of TIRADS and echogenic foci
    Su Min Ha, Yun Jae Chung, Hye Shin Ahn, Jung Hwan Baek, Sung Bin Park
    BMC Medical Imaging.2019;[Epub]     CrossRef
  • Risk of Malignancy According to the Sub-classification of Atypia of Undetermined Significance and Suspicious Follicular Neoplasm Categories in Thyroid Core Needle Biopsies
    Sae Rom Chung, Jung Hwan Baek, Jeong Hyun Lee, Yu-Mi Lee, Tae-Yon Sung, Ki-Wook Chung, Suck Joon Hong, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Won Gu Kim, Dong Eun Song
    Endocrine Pathology.2019; 30(2): 146.     CrossRef
  • Thyroid core needle biopsy: patients’ pain and satisfaction compared to fine needle aspiration
    Hyo Jin Kim, Yeo Koon Kim, Jae Hoon Moon, June Young Choi, Sang Il Choi
    Endocrine.2019; 65(2): 365.     CrossRef
  • Does Radiofrequency Ablation Induce Neoplastic Changes in Benign Thyroid Nodules: A Preliminary Study
    Su Min Ha, Jun Young Shin, Jung Hwan Baek, Dong Eun Song, Sae Rom Chung, Young Jun Choi, Jeong Hyun Lee
    Endocrinology and Metabolism.2019; 34(2): 169.     CrossRef
  • Differential Diagnosis of Thyroid Follicular Neoplasm from Nodular Hyperplasia by Shear Wave Elastography
    Myung Hi Yoo, Hye Jeong Kim, In Ho Choi, Ji-Oh Mok, Hyeong Kyu Park, Dong Won Byun, Kyoil Suh
    Soonchunhyang Medical Science.2019; 25(1): 10.     CrossRef
  • Ultrasound-Guided Core Needle Biopsy Techniques for Intermediate or Low Suspicion Thyroid Nodules: Which Method is Effective for Diagnosis?
    Soo Yeon Hahn, Jung Hee Shin, Young Lyun Oh, Ko Woon Park
    Korean Journal of Radiology.2019; 20(10): 1454.     CrossRef
  • Preoperative Diagnostic Categories of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features in Thyroid Core Needle Biopsy and Its Impact on Risk of Malignancy
    Hee Young Na, Ji Won Woo, Jae Hoon Moon, June Young Choi, Woo-Jin Jeong, Yeo Koon Kim, Ji-Young Choe, So Yeon Park
    Endocrine Pathology.2019; 30(4): 329.     CrossRef
  • Utility of a formatted pathologic reporting system in thyroid core needle biopsy: A validation study of 1998 consecutive cases
    Ji‐Young Choe, Yoonjin Kwak, Mimi Kim, Yul Ri Chung, Hyun Jeong Kim, Yeo Koon Kim, So Yeon Park
    Clinical Endocrinology.2018; 88(1): 96.     CrossRef
  • Nuclear features of papillary thyroid carcinoma: Comparison of Core needle biopsy and thyroidectomy specimens
    Jae Yeon Seok, Jungsuk An, Hyun Yee Cho, Younghye Kim, Seung Yeon Ha
    Annals of Diagnostic Pathology.2018; 32: 35.     CrossRef
  • Prevention of total thyroidectomy in noninvasive follicular thyroid neoplasm with papillary‐like nuclear features (NIFTP) based on combined interpretation of ultrasonographic and cytopathologic results
    Sung‐Hye You, Kyu Eun Lee, Roh‐Eul Yoo, Hye Jeong Choi, Kyeong Cheon Jung, Jae‐Kyung Won, Koung Mi Kang, Tae Jin Yoon, Seung Hong Choi, Chul‐Ho Sohn, Ji‐hoon Kim
    Clinical Endocrinology.2018; 88(1): 114.     CrossRef
  • Statement and Recommendations on Interventional Ultrasound as a Thyroid Diagnostic and Treatment Procedure
    Christoph F. Dietrich, Thomas Müller, Jörg Bojunga, Yi Dong, Giovanni Mauri, Maija Radzina, Manjiri Dighe, Xin-Wu Cui, Frank Grünwald, Andreas Schuler, Andre Ignee, Huedayi Korkusuz
    Ultrasound in Medicine & Biology.2018; 44(1): 14.     CrossRef
  • Core needle biopsy of thyroid nodules: outcomes and safety from a large single-center single-operator study
    Jooae Choe, Jung Hwan Baek, Hye Sun Park, Young Jun Choi, Jeong Hyun Lee
    Acta Radiologica.2018; 59(8): 924.     CrossRef
  • Improvement of diagnostic performance of pathologists by reducing the number of pathologists responsible for thyroid fine needle aspiration cytology: An institutional experience
    Jae Yeon Seok, Jungsuk An, Hyun Yee Cho
    Diagnostic Cytopathology.2018; 46(7): 561.     CrossRef
  • Comparison of Immunohistochemistry and Direct Sanger Sequencing for Detection of theBRAFV600EMutation in Thyroid Neoplasm
    Hye-Seon Oh, Hyemi Kwon, Suyeon Park, Mijin Kim, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Jene Choi, Won Gu Kim, Dong Eun Song
    Endocrinology and Metabolism.2018; 33(1): 62.     CrossRef
  • Comparison of the Diagnostic Efficacy of Ultrasound‐Guided Core Needle Biopsy With 18‐ Versus 20‐Gauge Needles for Thyroid Nodules
    Hye Shin Ahn, Mirinae Seo, Su Min Ha, Hee Sung Kim
    Journal of Ultrasound in Medicine.2018; 37(11): 2565.     CrossRef
  • Impact of Nodule Size on Malignancy Risk Differs according to the Ultrasonography Pattern of Thyroid Nodules
    Min Ji Hong, Dong Gyu Na, Jung Hwan Baek, Jin Yong Sung, Ji-Hoon Kim
    Korean Journal of Radiology.2018; 19(3): 534.     CrossRef
  • Web‐based thyroid imaging reporting and data system: Malignancy risk of atypia of undetermined significance or follicular lesion of undetermined significance thyroid nodules calculated by a combination of ultrasonography features and biopsy results
    Young Jun Choi, Jung Hwan Baek, Jung Hee Shin, Woo Hyun Shim, Seon‐Ok Kim, Won‐Hong Lee, Dong Eun Song, Tae Yong Kim, Ki‐Wook Chung, Jeong Hyun Lee
    Head & Neck.2018; 40(9): 1917.     CrossRef
  • Thyroid Incidentalomas Detected on18F-Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography: Malignant Risk Stratification and Management Plan
    Sae Rom Chung, Young Jun Choi, Chong Hyun Suh, Hwa Jung Kim, Jong Jin Lee, Won Gu Kim, Tae Yon Sung, Yu-mi Lee, Dong Eun Song, Jeong Hyun Lee, Jung Hwan Baek
    Thyroid.2018; 28(6): 762.     CrossRef
  • The role of core needle biopsy in the diagnosis of initially detected thyroid nodules: a systematic review and meta-analysis
    Sae Rom Chung, Chong Hyun Suh, Jung Hwan Baek, Young Jun Choi, Jeong Hyun Lee
    European Radiology.2018; 28(11): 4909.     CrossRef
  • The History of Korean Thyroid Pathology
    Soon Won Hong, Chan Kwon Jung
    International Journal of Thyroidology.2018; 11(1): 15.     CrossRef
  • Ultrasonographic Echogenicity and Histopathologic Correlation of Thyroid Nodules in Core Needle Biopsy Specimens
    Ji-hoon Kim, Dong Gyu Na, Hunkyung Lee
    Korean Journal of Radiology.2018; 19(4): 673.     CrossRef
  • Evaluation of Modified Core-Needle Biopsy in the Diagnosis of Thyroid Nodules
    Soomin Ahn, Sejin Jung, Ji-Ye Kim, Jung Hee Shin, Soo Yeon Hahn, Young Lyun Oh
    Korean Journal of Radiology.2018; 19(4): 656.     CrossRef
  • Role of core needle biopsy as a first-line diagnostic tool for thyroid nodules: a retrospective cohort study
    Min Ji Hong, Dong Gyu Na, Soo Jin Kim, Dae Sik Kim
    Ultrasonography.2018; 37(3): 244.     CrossRef
  • Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma: A Multi-Center Cohort Study in Korea
    Hye-Seon Oh, Jeonghoon Ha, Hye In Kim, Tae Hyuk Kim, Won Gu Kim, Dong-Jun Lim, Tae Yong Kim, Sun Wook Kim, Won Bae Kim, Young Kee Shong, Jae Hoon Chung, Jung Hwan Baek
    Thyroid.2018; 28(12): 1587.     CrossRef
  • Risk of malignancy according to sub‐classification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology
    S. J. Kim, J. Roh, J. H. Baek, S. J. Hong, Y. K. Shong, W. B. Kim, D. E. Song
    Cytopathology.2017; 28(1): 65.     CrossRef
  • Fine-needle aspiration versus core needle biopsy for diagnosis of thyroid malignancy and neoplasm: a matched cohort study
    Soo-Yeon Kim, Hye Sun Lee, Jieun Moon, Eun-Kyung Kim, Hee Jung Moon, Jung Hyun Yoon, Jin Young Kwak
    European Radiology.2017; 27(2): 801.     CrossRef
  • Follicular variant of papillary thyroid carcinoma: comparison of ultrasound-guided core needle biopsy and ultrasound-guided fine needle aspiration in a multicentre study
    Soo Yeon Hahn, Jung Hee Shin, Hyun Kyung Lim, So Lyung Jung
    Clinical Endocrinology.2017; 86(1): 113.     CrossRef
  • Core‐needle biopsy versus repeat fine‐needle aspiration for thyroid nodules initially read as atypia/follicular lesion of undetermined significance
    Young Jun Choi, Jung Hwan Baek, Chong Hyun Suh, Woo Hyun Shim, Boseul Jeong, Jae Kyun Kim, Dong Eun Song, Tae Yong Kim, Ki‐Wook Chung, Jeong Hyun Lee
    Head & Neck.2017; 39(2): 361.     CrossRef
  • Preoperative differentiation between noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) and non-NIFTP
    Soo Yeon Hahn, Jung Hee Shin, Hyun Kyung Lim, So Lyung Jung, Young Lyun Oh, In Ho Choi, Chan Kwon Jung
    Clinical Endocrinology.2017; 86(3): 444.     CrossRef
  • Core Needle Biopsy of the Thyroid: 2016 Consensus Statement and Recommendations from Korean Society of Thyroid Radiology
    Dong Gyu Na, Jung Hwan Baek, So Lyung Jung, Ji-hoon Kim, Jin Yong Sung, Kyu Sun Kim, Jeong Hyun Lee, Jung Hee Shin, Yoon Jung Choi, Eun Ju Ha, Hyun Kyung Lim, Soo Jin Kim, Soo Yeon Hahn, Kwang Hwi Lee, Young Jun Choi, Inyoung Youn, Young Joong Kim, Hye Sh
    Korean Journal of Radiology.2017; 18(1): 217.     CrossRef
  • First-Line Use of Core Needle Biopsy for High-Yield Preliminary Diagnosis of Thyroid Nodules
    H.C. Kim, Y.J. Kim, H.Y. Han, J.M. Yi, J.H. Baek, S.Y. Park, J.Y. Seo, K.W. Kim
    American Journal of Neuroradiology.2017; 38(2): 357.     CrossRef
  • Ultrasound-Pathology Discordant Nodules on Core-Needle Biopsy: Malignancy Risk and Management Strategy
    Sae Rom Chung, Jung Hwan Baek, Hye Sun Park, Young Jun Choi, Tae-Yon Sung, Dong Eun Song, Tae Yong Kim, Jeong Hyun Lee
    Thyroid.2017; 27(5): 707.     CrossRef
  • Current status of core needle biopsy of the thyroid
    Jung Hwan Baek
    Ultrasonography.2017; 36(2): 83.     CrossRef
  • Cytology-Ultrasonography Risk-Stratification Scoring System Based on Fine-Needle Aspiration Cytology and the Korean-Thyroid Imaging Reporting and Data System
    Min Ji Hong, Dong Gyu Na, Jung Hwan Baek, Jin Yong Sung, Ji-Hoon Kim
    Thyroid.2017; 27(7): 953.     CrossRef
  • Preoperative clinicopathological characteristics of patients with solitary encapsulated follicular variants of papillary thyroid carcinomas
    Hyemi Kwon, Min Ji Jeon, Jong Ho Yoon, Suck Joon Hong, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Won Gu Kim, Dong Eun Song
    Journal of Surgical Oncology.2017; 116(6): 746.     CrossRef
  • Active Surveillance for Patients With Papillary Thyroid Microcarcinoma: A Single Center’s Experience in Korea
    Hyemi Kwon, Hye-Seon Oh, Mijin Kim, Suyeon Park, Min Ji Jeon, Won Gu Kim, Won Bae Kim, Young Kee Shong, Dong Eun Song, Jung Hwan Baek, Ki-Wook Chung, Tae Yong Kim
    The Journal of Clinical Endocrinology & Metabolism.2017; 102(6): 1917.     CrossRef
  • Comparison of Consecutive Results from Fine Needle Aspiration and Core Needle Biopsy in Thyroid Nodules
    Soon-Hyun Ahn, So-Yeon Park, Sang Il Choi
    Endocrine Pathology.2017; 28(4): 332.     CrossRef
  • Efficacy and safety of core-needle biopsy in initially detected thyroid nodules via propensity score analysis
    Chong Hyun Suh, Jung Hwan Baek, Young Jun Choi, Tae Yong Kim, Tae Yon Sung, Dong Eun Song, Jeong Hyun Lee
    Scientific Reports.2017;[Epub]     CrossRef
  • Comparison of Core-Needle Biopsy and Fine-Needle Aspiration for Evaluating Thyroid Incidentalomas Detected by 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: A Propensity Score Analysis
    Chong Hyun Suh, Young Jun Choi, Jong Jin Lee, Woo Hyun Shim, Jung Hwan Baek, Han Cheol Chung, Young Kee Shong, Dong Eun Song, Tae Yon Sung, Jeong Hyun Lee
    Thyroid.2017; 27(10): 1258.     CrossRef
  • Thyroid Fine-Needle Aspiration Cytology Practice in Korea
    Yoon Jin Cha, Ju Yeon Pyo, SoonWon Hong, Jae Yeon Seok, Kyung-Ju Kim, Jee-Young Han, Jeong Mo Bae, Hyeong Ju Kwon, Yeejeong Kim, Kyueng-Whan Min, Soonae Oak, Sunhee Chang
    Journal of Pathology and Translational Medicine.2017; 51(6): 521.     CrossRef
  • Recent Advances in Core Needle Biopsy for Thyroid Nodules
    Chan Kwon Jung, Jung Hwan Baek
    Endocrinology and Metabolism.2017; 32(4): 407.     CrossRef
  • Core-needle biopsy for the preoperative diagnosis of follicular neoplasm in thyroid nodule screening: A validation study
    Sung Hak Lee, Gyeong Sin Park, So Lyung Jung, Min-Hee Kim, Ja Seong Bae, Dong Jun Lim, Chan Kwon Jung
    Pathology - Research and Practice.2016; 212(1): 44.     CrossRef
  • The Role of Core-Needle Biopsy as a First-Line Diagnostic Tool for Initially Detected Thyroid Nodules
    Chong Hyun Suh, Jung Hwan Baek, Jeong Hyun Lee, Young Jun Choi, Jae Kyun Kim, Tae-Yon Sung, Jong Ho Yoon, Young Kee Shong
    Thyroid.2016; 26(3): 395.     CrossRef
  • Thyroid nodules with minimal cystic changes have a low risk of malignancy
    Dong Gyu Na, Ji-hoon Kim, Dea Sik Kim, Soo Jin Kim
    Ultrasonography.2016; 35(2): 153.     CrossRef
  • Thyroid nodules with isolated macrocalcification: malignancy risk and diagnostic efficacy of fine-needle aspiration and core needle biopsy
    Dong Gyu Na, Dae Sik Kim, Soo Jin Kim, Jae Wook Ryoo, So Lyung Jung
    Ultrasonography.2016; 35(3): 212.     CrossRef
  • Thyroid Imaging Reporting and Data System Risk Stratification of Thyroid Nodules: Categorization Based on Solidity and Echogenicity
    Dong Gyu Na, Jung Hwan Baek, Jin Yong Sung, Ji-Hoon Kim, Jae Kyun Kim, Young Jun Choi, Hyobin Seo
    Thyroid.2016; 26(4): 562.     CrossRef
  • Fine‐needle aspiration and core needle biopsy: An update on 2 common minimally invasive tissue sampling modalities
    Paul A. VanderLaan
    Cancer Cytopathology.2016; 124(12): 862.     CrossRef
  • The role of core-needle biopsy in the diagnosis of thyroid malignancy in 4580 patients with 4746 thyroid nodules: a systematic review and meta-analysis
    Chong Hyun Suh, Jung Hwan Baek, Jeong Hyun Lee, Young Jun Choi, Kyung Won Kim, Jayoun Lee, Ki-Wook Chung, Young Kee Shong
    Endocrine.2016; 54(2): 315.     CrossRef
  • The Role of Core-Needle Biopsy for Thyroid Nodules with Initially Nondiagnostic Fine-Needle Aspiration Results: A Systematic Review and Meta-Analysis
    Chong Hyun Suh, Jung Hwan Baek, Kyung Won Kim, Tae Yon Sung, Tae Yong Kim, Dong Eun Song, Young Jun Choi, Jeong Hyun Lee
    Endocrine Practice.2016; 22(6): 679.     CrossRef
  • Should Core Needle Biopsy be Used in the Evaluation of Thyroid Nodules?
    Beril Guler, Tugce Kiran, Dilek Sema Arici, Erhan Aysan, Fatma Cavide Sonmez
    Endocrine Pathology.2016; 27(4): 352.     CrossRef
  • A Multicenter Prospective Validation Study for the Korean Thyroid Imaging Reporting and Data System in Patients with Thyroid Nodules
    Eun Ju Ha, Won-Jin Moon, Dong Gyu Na, Young Hen Lee, Nami Choi, Soo Jin Kim, Jae Kyun Kim
    Korean Journal of Radiology.2016; 17(5): 811.     CrossRef
  • Impact of Reclassification on Thyroid Nodules with Architectural Atypia: From Non-Invasive Encapsulated Follicular Variant Papillary Thyroid Carcinomas to Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features
    Min Ji Jeon, Dong Eun Song, Chan Kwon Jung, Won Gu Kim, Hyemi Kwon, Yu-Mi Lee, Tae-Yon Sung, Jong Ho Yoon, Ki-Wook Chung, Suck Joon Hong, Jung Hwan Baek, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Rafael Rosell
    PLOS ONE.2016; 11(12): e0167756.     CrossRef
Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group
Hyojin Kim, Hyo Sup Shim, Lucia Kim, Tae-Jung Kim, Kun Young Kwon, Geon Kook Lee, Jin-Haeng Chung
Korean J Pathol. 2014;48(1):1-9.   Published online February 25, 2014
DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.1.1
  • 12,853 View
  • 122 Download
  • 19 Crossref
AbstractAbstract PDF

Rearrangement of anaplastic lymphoma kinase (ALK) gene is the best predictor of response to crizotinib, an ALK tyrosine kinase inhibitor. However, the prevalence of the ALK fusion is low, so accurate patient identification is crucial for successful treatment using ALK inhibitors. Furthermore, most patients with lung cancer present with advanced-stage disease at the time of diagnosis, so it is important for pathologists to detect ALK-rearranged patients while effectively maximizing small biopsy or cytology specimens. In this review, we propose a guideline recommendation for ALK testing approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.

Citations

Citations to this article as recorded by  
  • Molecular Characteristics of Radon Associated Lung Cancer Highlights MET Alterations
    Gabriele Gamerith, Marcel Kloppenburg, Finn Mildner, Arno Amann, Sabine Merkelbach-Bruse, Carina Heydt, Janna Siemanowski, Reinhard Buettner, Michael Fiegl, Claudia Manzl, Georg Pall
    Cancers.2022; 14(20): 5113.     CrossRef
  • ALK Translocation in ALK-Positive Mesenchymal Tumors: Diagnostic and Therapeutic Insights
    Minsun Jung, Kyung Chul Moon, Jeongmo Bae, Tae Min Kim, Miso Kim, Yoon Kyung Jeon, Cheol Lee
    Archives of Pathology & Laboratory Medicine.2022; 146(12): 1460.     CrossRef
  • Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
    Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
    Journal of Pathology and Translational Medicine.2021; 55(3): 181.     CrossRef
  • Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets
    Mercedes L Dalurzo, Alejandro Avilés-Salas, Fernando Augusto Soares, Yingyong Hou, Yuan Li, Anna Stroganova, Büge Öz, Arif Abdillah, Hui Wan, Yoon-La Choi
    OncoTargets and Therapy.2021; Volume 14: 4671.     CrossRef
  • Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society
    Pathmanathan Rajadurai, Phaik Leng Cheah, Soon Hin How, Chong Kin Liam, Muhammad Azrif Ahmad Annuar, Norhayati Omar, Noriah Othman, Nurhayati Mohd Marzuki, Yong Kek Pang, Ros Suzanna Ahmad Bustamam, Lye Mun Tho
    Lung Cancer.2019; 136: 65.     CrossRef
  • Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors
    Neal I. Lindeman, Philip T. Cagle, Dara L. Aisner, Maria E. Arcila, Mary Beth Beasley, Eric H. Bernicker, Carol Colasacco, Sanja Dacic, Fred R. Hirsch, Keith Kerr, David J. Kwiatkowski, Marc Ladanyi, Jan A. Nowak, Lynette Sholl, Robyn Temple-Smolkin, Benj
    Journal of Thoracic Oncology.2018; 13(3): 323.     CrossRef
  • Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors
    Neal I. Lindeman, Philip T. Cagle, Dara L. Aisner, Maria E. Arcila, Mary Beth Beasley, Eric H. Bernicker, Carol Colasacco, Sanja Dacic, Fred R. Hirsch, Keith Kerr, David J. Kwiatkowski, Marc Ladanyi, Jan A. Nowak, Lynette Sholl, Robyn Temple-Smolkin, Benj
    The Journal of Molecular Diagnostics.2018; 20(2): 129.     CrossRef
  • Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the
    Neal I. Lindeman, Philip T. Cagle, Dara L. Aisner, Maria E. Arcila, Mary Beth Beasley, Eric H Bernicker, Carol Colasacco, Sanja Dacic, Fred R. Hirsch, Keith Kerr, David J. Kwiatkowski, Marc Ladanyi, Jan A. Nowak, Lynette Sholl, Robyn Temple-Smolkin, Benja
    Archives of Pathology & Laboratory Medicine.2018; 142(3): 321.     CrossRef
  • 5′/ 3′ imbalance strategy to detect ALK fusion genes in circulating tumor RNA from patients with non-small cell lung cancer
    Yongqing Tong, Zhijun Zhao, Bei Liu, Anyu Bao, Hongyun Zheng, Jian Gu, Mary McGrath, Ying Xia, Bihua Tan, Chunhua Song, Yan Li
    Journal of Experimental & Clinical Cancer Research.2018;[Epub]     CrossRef
  • Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study
    Dae Ho Lee, Ming-Sound Tsao, Karl-Otto Kambartel, Hiroshi Isobe, Ming-Shyan Huang, Carlos H. Barrios, Adnan Khattak, Filippo de Marinis, Smita Kothari, Ashwini Arunachalam, Xiting Cao, Thomas Burke, Amparo Valladares, Javier de Castro, Aamir Ahmad
    PLOS ONE.2018; 13(8): e0202865.     CrossRef
  • Microfluidics-based immunofluorescence for fast staining of ALK in lung adenocarcinoma
    Saška Brajkovic, Benjamin Pelz, Maria-Giuseppina Procopio, Anne-Laure Leblond, Grégoire Repond, Ariane Schaub-Clerigué, Diego G Dupouy, Alex Soltermann
    Diagnostic Pathology.2018;[Epub]     CrossRef
  • Expanded Circulating Tumor Cells from a Patient with ALK- Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study
    Zhuo Zhang, Hiroe Shiratsuchi, Nallasivam Palanisamy, Sunitha Nagrath, Nithya Ramnath
    Journal of Thoracic Oncology.2017; 12(2): 397.     CrossRef
  • Molecular Testing of Lung Cancers
    Hyo Sup Shim, Yoon-La Choi, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Mee Sook Roh, Tae-Jung Kim, Seung Yeon Ha, Jin-Haeng Chung, Se Jin Jang, Geon Kook Lee
    Journal of Pathology and Translational Medicine.2017; 51(3): 242.     CrossRef
  • Novel ALK fusion partners in lung cancer
    Aglaya G. Iyevleva, Grigory A. Raskin, Vladislav I. Tiurin, Anna P. Sokolenko, Natalia V. Mitiushkina, Svetlana N. Aleksakhina, Aigul R. Garifullina, Tatiana N. Strelkova, Valery O. Merkulov, Alexandr O. Ivantsov, Ekatherina Sh. Kuligina, Kazimir M. Pozha
    Cancer Letters.2015; 362(1): 116.     CrossRef
  • Strategic management of transthoracic needle aspirates for histological subtyping and EGFR testing in patients with peripheral lung cancer: An institutional experience
    Choonhee Son, Eun‐Ju Kang, Mee Sook Roh
    Diagnostic Cytopathology.2015; 43(7): 532.     CrossRef
  • Current and future molecular diagnostics in non-small-cell lung cancer
    Chun Man Li, Wing Ying Chu, Di Lun Wong, Hin Fung Tsang, Nancy Bo Yin Tsui, Charles Ming Lok Chan, Vivian Wei Wen Xue, Parco Ming Fai Siu, Benjamin Yat Ming Yung, Lawrence Wing Chi Chan, Sze Chuen Cesar Wong
    Expert Review of Molecular Diagnostics.2015; 15(8): 1061.     CrossRef
  • Role of biopsy sampling for diagnosis of early and progressed hepatocellular carcinoma
    Haeryoung Kim, Young Nyun Park
    Best Practice & Research Clinical Gastroenterology.2014; 28(5): 813.     CrossRef
  • Molecular Pathology of Lung Cancer: Current Status and Future Directions
    Mee Sook Roh
    Tuberculosis and Respiratory Diseases.2014; 77(2): 49.     CrossRef
  • Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity
    Sung-Jun Ko, Yeon Joo Lee, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Jin-Haeng Chung, Tae Jung Kim, Kyung Won Lee, Kwhanmien Kim, Sanghoon Jheon, Hyojin Kim, Jae Ho Lee, Choon-Taek Lee
    BMC Cancer.2014;[Epub]     CrossRef
Review & Perspective
Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group
Hyo Sup Shim, Jin-Haeng Chung, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Geon Kook Lee, Soon-Hee Jung, Se Jin Jang
Korean J Pathol. 2013;47(2):100-106.   Published online April 24, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.2.100
  • 9,770 View
  • 85 Download
  • 12 Crossref
AbstractAbstract PDF

Mutations of the epidermal growth factor receptor (EGFR) are the strongest predictive factor for response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. EGFR TKIs are approved in Korea as a first-line treatment for lung cancer patients with mutated EGFR. Rapid and accurate EGFR mutation testing is essential for patient selection and establishing targeted therapies with EGFR TKIs. Thus, a standard set of guideline recommendations for EGFR mutation testing suitable for the Korean medical community is necessary. In this article, we propose a set of guideline recommendations for EGFR mutation testing that was discussed and approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.

Citations

Citations to this article as recorded by  
  • Favorable Conditions for the Detection of EGFR T790M Mutation Using Plasma Sample in Patients with Non-Small-Cell Lung Cancer
    Insu Kim, Hee Yun Seol, Soo Han Kim, Mi-Hyun Kim, Min Ki Lee, Jung Seop Eom
    Cancers.2023; 15(5): 1445.     CrossRef
  • Novel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer
    Dorine de Jong, Jeeban P. Das, Hong Ma, Jacienta Pailey Valiplackal, Conor Prendergast, Tina Roa, Brian Braumuller, Aileen Deng, Laurent Dercle, Randy Yeh, Mary M. Salvatore, Kathleen M. Capaccione
    Cancers.2023; 15(10): 2855.     CrossRef
  • Coordination games in cancer
    Péter Bayer, Robert A. Gatenby, Patricia H. McDonald, Derek R. Duckett, Kateřina Staňková, Joel S. Brown, Jun Tanimoto
    PLOS ONE.2022; 17(1): e0261578.     CrossRef
  • Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
    Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
    Journal of Pathology and Translational Medicine.2021; 55(3): 181.     CrossRef
  • Primary HHV-8 (-) Effusion-Based Non-Germinal Center B Cell Diffuse Large B Cell Lymphoma Successfully Treated with Standard Anthracycline-Based Chemoimmunotherapy
    Justin J Kuhlman, Muhamad Alhaj Moustafa, Liuyan Jiang, Han W Tun
    Journal of Blood Medicine.2021; Volume 12: 833.     CrossRef
  • Molecular Testing of Lung Cancers
    Hyo Sup Shim, Yoon-La Choi, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Mee Sook Roh, Tae-Jung Kim, Seung Yeon Ha, Jin-Haeng Chung, Se Jin Jang, Geon Kook Lee
    Journal of Pathology and Translational Medicine.2017; 51(3): 242.     CrossRef
  • Strategic management of transthoracic needle aspirates for histological subtyping and EGFR testing in patients with peripheral lung cancer: An institutional experience
    Choonhee Son, Eun‐Ju Kang, Mee Sook Roh
    Diagnostic Cytopathology.2015; 43(7): 532.     CrossRef
  • Ultrasonography-Guided Core Biopsy of Supraclavicular Lymph Nodes for Diagnosis of Metastasis and Identification of Epidermal Growth Factor Receptor (EGFR) Mutation in Advanced Lung Cancer
    Jooae Choe, Mi Young Kim, Jung Hwan Baek, Chang-Min Choi, Hwa Jung Kim
    Medicine.2015; 94(29): e1209.     CrossRef
  • Reliable EGFR mutation testing in ultrasound-guided supraclavicular lymph node fine-needle aspirates: a cohort study with diagnostic performance analysis
    Amir Awwad, Sandeep Tiwari, Vishakha Sovani, David R Baldwin, Maruti Kumaran
    BMJ Open Respiratory Research.2015; 2(1): e000075.     CrossRef
  • Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non‐small‐cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage
    Tae‐Jung Kim, Chan Kwon Park, Chang Dong Yeo, Kihoon Park, Chin Kook Rhee, Jusang Kim, Seung Joon Kim, Sang Haak Lee, Kyo‐Young Lee, Hyoung‐Kyu Yoon
    Journal of Surgical Oncology.2014; 110(3): 245.     CrossRef
  • Novel EGFR mutation-specific antibodies for lung adenocarcinoma: Highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry
    An Na Seo, Tae-In Park, Yan Jin, Ping-Li Sun, Hyojin Kim, Hyun Chang, Jin-Haeng Chung
    Lung Cancer.2014; 83(3): 316.     CrossRef
  • Molecular Pathology of Lung Cancer: Current Status and Future Directions
    Mee Sook Roh
    Tuberculosis and Respiratory Diseases.2014; 77(2): 49.     CrossRef
Original Article
Guidelines for Pathologic Study of Gastric Cancer.
Korean J Pathol. 1992;26(2):154-163.
  • 1,590 View
  • 36 Download
AbstractAbstract PDF
Gastric cancer is the most common malignant neoplasm among Koreans, and the pathologists's daily diagnostic competency on gastric cancer at any hospital setting plays a critical implication not only in the quality of clinical service but also to the determination of patient's prognosis. Thus, adoption of a unified assessment system based on comprehensive understanding of pathologic features together with their active participation has been crucially demanded. Nevertheless, a considerable difference in handling procedures and diagnostic approach on gastric cancer among institutions apparently resulted in an extreme difficulty in exchange of clinicopathologic informations and in the nationwide survey. It is, therefore, essential and be the first step to develop a practical but scientific and reproducible classification of gastric cancer with its diverse gross and histologic findings. Based on the following basic principles, the Subcommittee on Gastric Cancer under the Gastrointestinal Study Group of the Korean Society of Pathologists has been requested to develop the guidelines of future pathologic study of gastric cancer to meet the above needs and be efficiently used with ease among the society members. 1) The prerequisite for pathologic classification of gastric cancer starts with consistency in handling of the resected stomach before its further examination. Thus, the guideline shall limits its scope only with the minimum agreement. 2) The classification should be simple and practical so that all pathologists can use with ease and with high reproducibility. 3) All the gross and microscopic findings which have been considered to be the prognosis-related factors should be included in every pathologic procedures to help future information exchange among pathologists and clinicians and to provide a meaningful role in determination of patient's prognosis. 4) The classification should be interchangeable and stand with compatibility among WHO and other internationally accepted classifications. 5) The guideline accepts in part the staging system of American Joint Commitee on Cancer, classification of early gastric cancer proposed by the Japanese Society of Gastrointestinal Endoscopy, and the General Rules of Stomach Cancer Study by Japanese Research Society of Gastric Cancer, until otherwise developed and accepted by the Korean Society of Pathologists. 6) The guideline should not interfere with each institution-based special study. The details of the handling procedures of the resected stomach cancer, its gross and histologic classifications and descriptive methods of prognostic factors are supplemented with illustrations.

J Pathol Transl Med : Journal of Pathology and Translational Medicine
TOP